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Summary: 
Cell-to-cell communication plays an important role in multicellular tissues. It is also  
pivotal in the modulation of vessel functions, such as the regulation of vessel tone. 
Heterocellular communication between endothelial cells (EC) and vascular smooth 
muscle cells (VSMC) via myoendothelial gap junctions (MEGJs) represents an 
important communication pathway in resistance arteries and arterioles. 
Myoendothelial junctions (MEJ) are, however, not only the site of direct cell 
communication via gap junctions but also represent a signaling microdomain critical 
for localizing, concentrating, and organizing cell-signaling components and regulating 
various vascular biological processes such as endothelium dependent 
hyperpolarization (EDH) of vascular smooth muscle. Therefore, a better 
understanding of MEJ’s physiological functions allows new insights into regulation of 
vessel function. Up to now, little is known, however, about the regulation for MEJ 
formation.  
The 5’-adenosine monophosphate-activated protein kinase (AMPK) is not only one of 
the most important enzymes controlling cell catabolic metabolism, but has been 
shown to influence vascular tone, thereby augmenting  blood and oxygen supply  as 
required for catabolic pathways. It has not yet been studied, however, whether AMPK 
could also affect MEJ. Thus, the aim of this project was to elucidate the impact of 
AMPK on MEJ dynamics and its potential mechanism of action. 
We studied isolated small mesenteric and skeletal muscle resistance arteries of mice 
using a pressure myograph system developed in our laboratory. Using confocal and 
two photon excitation fluorescence microscopy we identified the internal elastic 
lamina, which in these vessels exhibits small holes that allow direct contact between 
endothelial and smooth muscle cells. On average, we found that in about 35% of the 
holes, structures with a bright actin core as assessed by using F-actin fluorescence in 
LifeAct mice or by staining with phalloidin which we could define as sites of MEJ. 
These structures showed expression of Cx37 and Cx43 suggesting that MEGJs were 
also localized in these structures. We found that endoplasmic reticulum (ER) was 
enriched around MEJs which is consistent with MEJs acting as active signaling 
domains. Over observation time of up to 2 hours, we found that the number and 
localization of these MEJ varied, while they always showed expression in the area of 
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holes of IEL only. Thus, for the first time we could investigate MEJ dynamics. AMPK 
negatively regulates MEJ expression, since in AMPK α1, but not in α2 knockout (KO) 
mice, the number of MEJ was significantly increased. In accordance, in wild type 
mice, incubation with the AMPK inhibitory compound C (CC) significantly augmented 
the number of MEJ while the AMPK stimulator A76 did not further decrease them 
during the observation time. Furthermore, we found that the KO of AMPK α1, in intact 
mice as well as in cultured human and porcine smooth muscle cells, went along with 
an increase in PAI-1 expression. Accordingly, incubation of arteries with exogenous 
PAI-1 also increased the number of MEJ. The negative effect of AMPK on PAI-1 
could be explained by enhanced expression of the silencer of the PAI-1 gene, small 
heterodimer partner (SHP). PAI-1 expression in arteries from AMPK α2 KO mice was 
unchanged compared to arteries from WT mice.  
Since MEJ are also involved in EDH, we studied whether the expression of MEJ 
correlated with EDH induced vasodilation. The higher amount of MEJs in α1 KO mice 
went indeed along with a left shift of acetylcholine (ACh) -induced dilation dose effect 
curve.  
In summary, this work describes for the first time a role of AMPK as a potent 
modulator of MEJ dynamics. This effect is selectively mediated by the α1 subunit of 
AMPK which is probably mediated by controlling PAI-1 expression. Our data also for 
the first time demonstrate a dynamic regulation of MEJ expression in intact blood 
vessels. Since MEJ represent a gateway for the communication between EC and 
VSMC and are involved in EDH, our observations may point towards a new target 
with therapeutic potential in small resistance vessels.    
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Zusammenfassung: 
Die Zell-zu-Zell-Kommunikation spielt in multizellulären Geweben  eine wichtige Rolle. Diese 
Kommunikation ist auch bei der Modulation der Gefäßfunktion, wie beispielsweise bei der 
Regulierung des Gefäßtonus von großer Bedeutung. Myoendotheliale gap junctions (MEGJs) 
ermöglichen eine heterozelluläre Kommunikation zwischen Endothelzellen (EC) und glatten 
Gefäßmuskelzellen (VSMC). Sie sind in myoendothelialen Junctions (MEJ) lokalisiert. MEJ  
stellen darüber hinaus eine Signalmikrodomäne dar, die für die Lokalisierung, Konzentration 
und Organisation von Zellsignalen und die Regulierung verschiedener vaskulärer Prozesse 
von entscheidender Bedeutung ist. Dazu gehört auch die endothel-abhängige 
Hyperpolarisation (EDH) der Gefäßmuskulatur welche eine Gefäßerweiterung auslöst. Ein 
besseres Verständnis der Dynamik der MEJ kann daher neue Einsichten in die Regulation von 
Gefäßfunktionen vermitteln. 
Die 5'-Adenosinmonophosphat-aktivierte Proteinkinase (AMPK) ist nicht nur eines der 
wichtigsten Enzyme für die Kontrolle der Zellmetabolismus sondern spielt auch eine 
wesentliche Rolle bei der Kontrolle des Gefäßtonus. Die Enzymaktivierung führt zu einer 
Vasodilatation welche die Blut- und Sauerstoffversorgung der Gewebe verbessert. Es wurde 
jedoch bisher noch nicht untersucht, ob AMPK auch die Bildung von MEJ beeinflusst. Daher 
war es das Ziel dieses Projekts, den Einfluss von AMPK auf die MEJ-Dynamik und potentielle 
Mechanismen, die diesem Einfluss zu Grunde liegen, aufzuklären.  
Unsere Untersuchungen führten wir in kleinen Widerstandsarterien durch,  welche aus der 
Skeletmuskulatur  bzw. dem Mesenterium von Mäusen frisch isoliert wurden. Unter 
Verwendung von konfokaler und 2-Photonen Mikroskopie  konnten wir in diesen Gefäßen 
die Lamina Elastica Interna (IEL) darstellen, welche Endothel- und Gefäßmuskelzellen 
voneinander trennt, aber zahlreiche Löcher aufweist. Nur in diesen Bereichen ist ein direkter 
Kontakt zwischen Endothel und Gefäßmuskelzellen möglich. Bei genauer Analyse fanden wir 
heraus, dass in etwa 35% der Löcher Strukturen sichtbar waren, welche gleichermaßen von 
Gefäßmuskulatur und Endothel ausgingen und sich durch ein sehr deutliches F-Aktin 
Fluoreszenz-Signal auszeichneten (LifeAct oder Phalloidin Staining) und die wir als 
myoendotheliale Junctions (MEJ) definieren konnten.  In diesen Strukturen ließen sich auch 
die Connexine Cx37 und Cx43 nachweisen, was auf das Vorhandensein von 
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myoendothelialen Gap Junctions in diesen Bereichen hinwies.  Im Bereich der MEJ war 
ebenfalls endoplasmatisches Retikulum nachzuweisen, was zusätzlich darauf hinwies, dass 
es sich um eine signalaktive Domäne handelte. Während Beobachtungszeiten von bis zu 2 
Stunden variierte die Zahl  und  Lokalisation der MEJ, war jedoch stets nur im Bereich von 
Löchern der LEI nachzuweisen. Damit war es zum ersten Mal möglich, die Dynamik von MEJ 
zu untersuchen. Die Untersuchungen identifizierten AMPK als  negativen Regulator der MEJ. 
In AMPK1 KO Mäusen war die Zahl der  MEJ signifikant erhöht, während in AMPK2 KO 
Mäusen keine Veränderungen gegenüber Wildtyp Kontrollen nachweisbar waren. In 
Übereinstimmung mit diesen Beobachtungen nahm die Zahl der MEJ auch nach akuter Gabe 
des AMPK Inhibitors Compound C signifikant zu, während es unter pharmakologischer 
Stimulation der  AMPK zu keiner  weiteren Abnahme kam. Der Knockout von AMPK1 in 
isolierten Gefäßen bzw. auch in kultivierten Gefäßmuskelzellen (mittels siRNA) ging mit einer 
signifikanten Zunahme der Expression von Plasminaktivator Inhibitor 1 (PAI-1) einher. Die 
akute Gabe von PAI-1 führte ebenfalls zu einer Zunahme von MEJ. Der negative Effekt von 
AMPK auf die PAI-1 Expression war möglicherweise über eine Hemmung der PAI-1 
Genexpression durch SHP (small heterodimer partner) verursacht, da SHP in AMPK KO 
vermindert exprimiert war.  
Da die EDH über MEJ vermittelt wird, untersuchten wir auch, ob eine gesteigerte Zahl von 
MEJ mit einer verstärkten EDH einhergeht. In der Tat war die durch  Acetylcholin ausgelöste 
und durch EDH vermittelte Gefäßdilatation in Gefäßen von AMPK1 KO Mäusen  signifikant 
verstärkt. 
Zusammenfassend beschreibt diese Arbeit erstmalig eine Dynamik der MEJ in intakten 
kleinen Blutgefäßen. Sie zeigt aber auch eine Rolle von AMPK bei der Kontrolle der MEJ 
Expression, welche  vermutlich über PAI-1 vermittelt wird. Da MEJ eine  zentrale 
Schnittstelle zwischen Endothel und Gefäßmuskel, u. a. für die EDH,  darstellen, tragen 
unsere Untersuchungen dazu bei, MEJ und AMPK als mögliche Angriffspunkte für die 
therapeutische Beeinflussung der Gefäßfunktion in den Blick zu nehmen.  
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1. Introduction: 
1.1. Cell–Cell Communication 
Cell-to-cell communication is essential for biological processes such as differentiation, 
development and for maintaining normal function in multicellular organisms 
(Bloemendal & Kück 2013). Communication happens both in homotypic and 
heterotypic cells. The communication can be divided into two types according to the 
distance between cells: distant and local communication (Ha et al. 2016). The distant 
communication occurs through hormones, such as insulin which is secreted from 
pancreas, and reaches their target cells via the blood stream. By distant 
communication, various types of cells and organs in whole body expressing the 
respective receptor can be regulated (Röder et al. 2016). Recently, a novel distant 
intercellular communication via exosomes has been reported (Kowal et al. 2016). 
Exosomes are membrane vesicles which contain various contents, among them 
including proteins and RNAs. They can reach their target cells via the blood stream 
or other biological fluids. After contact with the target cells they release their 
constituents (Junyan Xu et al. 2017). The local communication include short range 
diffusion of transmitters and paracrine factors (indirect contact) such as synaptic 
transmission, and the direct intercellular exchange of (signal) molecules or electric 
signals via gap junctions (GJ) or tunneling nanotubes (TNT) (Ha et al. 2016; Nawaz 
et al. 2017; Rustom et al. 2014; Abounit & Zurzolo 2012). GJs are present in a wide 
variety of cells and play pivotal roles in a variety of biological processes, like 
development, differentiation, neural activity, immune response and vascular tone 
(Maeda & Tsukihara 2011; Zhang & Ducsay 2014). GJs were discovered more than 
50 years ago (Revel & Karnovsky 1967). With ongoing research, it became evident 
that GJs are channels which allow the exchange of small molecules and current 
between adjacent cells. An intercellular GJ channel is comprised of two connexons 
formed with six connexin monomers in hexagonal configuration (Yeager & Harris 
2007) being located in the corresponding membrane sites of two adjacent cells. 
There are 21 different connexins in humans, of which the connexins 37, 40, 43 and 
45 are verified to be present in vascular cells (Isakson & Duling 2005; Heberlein et al. 
2009). 
Cell-cell communication also plays a pivotal role in the regulation of blood vessel 
function (Figueroa & Duling 2009). The vascular system principally consists of 
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arteries, veins and capillaries. Normally, the resistance arteries and arterioles are 
responsible for controlling the magnitude and the distribution of organ blood flow 
(Jacob et al. 2016). The arterial wall can be subdivided into tunica adventitia, media 
and intima, which are separated by external elastic lamina (EEL) and internal elastic 
lamina (IEL) respectively (Dora 2001; Welsh & Taylor 2012). The adventitia is mostly 
composed of connective tissue, fibroblasts and the nerves; the media is mostly 
composed of vascular smooth muscle cell (VSMC) and the intima is composed of a 
monolayer of endothelial cells (EC) (Tennant & Mcgeachie 1990). According to the 
structure of wall, there are homocellular and heterocellular communications in the 
blood vessel. The homocellular communications mainly include the VSMC-VSMC 
and EC-EC communications. These communications play an important role in the cell 
synchronization and coordination of a vessel (Schmidt et al. 2008). The heterocellular 
communications not only include nerve-EC and nerve-VSMC communications (Dora 
2001) but, in addition, heterocellular communications between EC and VSMC are 
named as the myoendothelial junctions (MEJs) (Sandow & Hill 2000b). MEJs not only 
exists myoendothelial gap junctions (MEGJs) pathway for the communication 
between EC and VSMC, but also represent a signaling microdomain critical for 
localizing, concentrating, and organizing cell-signaling components and regulating 
various vascular biological processes such as endothelium dependent 
hyperpolarization (EDH) of VSMC in resistance arteries and arterioles (Sandow et al. 
2002). 
1.2. Myoendothelial junction (MEJ) in the vasculature 
Myoendothelial junctions (MEJs) are the regions where VSMCs and ECs get in close 
contact to each other through the fenestrations of IEL via their projections (Straub et 
al. 2014). In these areas also myoendothelial gap junctions (MEGJ) can be formed. 
MEJs were first found sixty years ago at the ultrastructure level in a transmission 
electron microscopy (TEM) study on small canine arteries (Moore & Ruska 1957). 
Fifty years ago, its high resolution images were obtained from rabbit kidney 
arterioles, and MEJs were proposed to serve as channels for communications 
between ECs and VSMCs (Rhodin 1967). Nearly twenty years ago, an exquisite 
three dimensional reconstruction of MEJ was performed from TEM sections which 
confirmed again that MEJ exists between EC and VSMC (Sandow & Hill 2000b). With 
regard to the morphology of the cellular processes, MEJs can be divided into three 
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different types: first, VSMC protrusions contact with EC through the IEL; second, EC 
protrusions contact with VSMC through IEL; third, VSMC and EC protrusions contact 
halfway between each other cell in the IEL (Michel et al. 1995). The shape of MEJ 
are club-like or flat appositions, about 0.5 µm in width by 0.5 µm in depth (Straub et 
al. 2014). The different shapes may relate to different specific functions or 
developmental stages of MEJs (Heberlein et al. 2009). On a subcellular basis, it has 
been found that endoplasmic reticulum (ER), cytoskeletal components, caveolae, 
IP3-R1 and some ion channels such as KCa2.3 channel, KCa3.1 channel are enriched 
in MEJs (Dora et al. 2009; Heberlein et al. 2009) together with gap junctions. 
Connexin 37, 40, 43 have been reported to be present in MEJ so far (Haddock et al. 
2006; Isakson, A. K. Best, et al. 2008; Sandow et al. 2006). They can form gap 
junctions but also exert channel independent functions (Kameritsch et al. 2015). The 
structure of a MEJ is shown schematically in (Figure 1). The frequency of MEJs in 
vasculature is variable depending on the organs and species. The accepted 
tendency is that in the adult state MEJs do not exist in aorta and large arteries, 
whereas in the microcirculation, MEJs are expressed and their number increases 
with decrease vessel diameter (Sandow et al. 2012). 
In general, it is now widely accepted that the MEJs do not only allow for direct 
transfer of substances between EC and VSMC through gap junctions located in this 
area (Straub et al. 2014), but also represent a signaling microdomain critical for 
localizing, concentrating, and organizing cell-signaling components and regulating 
various vascular biological processes (Heberlein et al. 2009). The nitric oxide (NO) 
generating enzyme endothelial nitric oxide synthase (eNOS), which is an important 
factor regulating the vascular tone and for preventing proliferation of VSMC, exists in 
close apposition to MEJ (Straub et al. 2011; Straub et al. 2012). MEJs can also 
specifically enable control of the abluminal pool of eNOS in EC (Biwer et al. 2016). 
Endothelium-dependent hyperpolarization (EDH) is another of the three important 
endothelial dilator mechanisms, and the MEJ has been shown to be essentially 
involved in EDH of VSM (Sandow & Hill 2000a; Sandow et al. 2002). Moreover, our 
group reported that MEGJs regulate the bidirectional Ca2+-signal propagation 
between EC and VSMC (Pogoda et al. 2014). MEGJs also join in the regulation of 
coronary VMSC differentiation by shear stress (Zhang et al. 2016). The transfer of 
VSMC from contractile to synthetic phenotype plays a pivotal role in intimal 
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hyperplasia of vessels in atherosclerosis. As a consequence, MEJs dysfunction might 
be involved in arteriosclerosis (Zhang et al. 2016). 
MEGJs are very dynamic with regard to their permeability as well as their expression 
in the membrane. The regulation of gap junction permeability occurs via 
posttranslational modification of the cytosolic parts of the connexins, in particular, the 
C-terminus. (Segal & Bagher 2010). For example, our group has shown that NO can  
reduce the calcium signal exchange via MEJ via tyrosine de-phosphorylation of 
connexin37 (Cx37) at position 332 (Pogoda et al. 2017).  
In contrast, our knowledge about which factors influence the formation and 
regression of MEJ which are required for formation of MEJ are still limited. However, 
one of the regulators in the coagulation system, the plasminogen activator inhibitor-1 
(PAI-1) has been reported to play an important role on MEJ formation (Segal & 
Bagher 2010; Heberlein et al. 2010). To study the role of MEJ, mostly cell co-culture 
models have been used  (Wallace et al. 2007). TEM was used in intact arteries 
(Heberlein et al. 2010). These approaches do, however, allow neither to study the 
dynamics of the MEJ in living tissue in situ nor the consequences on the regulation of 
vascular tone.   
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Figure 1. Schematic structure of MEJ. 
A MEJ is formed by protrusions of EC and VSM in a hole of the IEL. In this functional domain 
many channels and subcellular structures are located. For more details, see text.  
1.3. Plasminogen activator inhibitor-1  
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor. It is a 
glycoprotein and was discovered more than 30 years ago (Pannekoek et al. 1986). 
Many cell types can synthesize PAI-1, among them are VSMC, EC, hepatocytes and 
some other mesenchymal cells (Dimova & Kietzmann 2008). Platelets can also 
synthesize PAI-1, and they can store it in alpha granules (Brogren et al. 2004; 
Erickson et al. 1984). PAI-1 exists in three states: active, latent and inactive (Lindahl 
et al. 1989). Normally, PAI-1 is secreted in the active state and will be converted into 
the inactive state with a half life time of about 1-2 hours at 37 °C (Lindahl et al. 1989). 
The important function of PAI-1 is to serve as an inhibitor of urokinase-type 
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plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), thereby  
modulating the balance between blood coagulation and the fibrinolytic process 
(Rijken & Lijnen 2009). However, additional functions of PAI-1 are being unveiled. 
Recently, the influence of PAI-1 on MEJ dynamics has also been described (Segal & 
Bagher 2010; Heberlein et al. 2010)  
With regard to blood vessels, PAI-1 has so far been found to play a role mainly under 
pathophysiologic conditions. PAI-1 is involved in many vascular diseases, such as 
atherosclerosis, neointima hyperplasia (Zhu et al. 2001; Deyoung et al. 2001) and 
restenosis (Prisco et al. 2001), via its influence on VSMC migration, detachment and 
adhesion. High level of PAI-1 represents also an independent factor for predicting 
development of type 2 diabetes mellitus (DM) (Festa et al. 2002), which is positively 
linked to development of cardiovascular disease (CVD).  
As PAI-1 seems to be a crucial factor for CVD, DM and some others diseases, the 
research activities regarding its regulation are increasing. The regulation of PAI-1 
synthesis can occur at both, the  transcriptional and the post-transcriptional level 
(Agirbasli 2005). Inflammation seems to be a potent stimulator of PAI-1 production. 
For example, interleukin-1(IL-1) (Emeis & Kooistra 1986) and tumor necrosis factor-α 
(TNF-α) (Sawdey et al. 1989) can stimulate cultured EC to increase PAI-1 
expression, and hypoxia is also a stimulator for increasing PAI-1 synthesis in EC 
(Gerber et al. 1993). Moreover, high glucose level can enhance PAI-1 gene 
expression by activation of PAI-1 promoter via Sp1 site (Chen et al. 1998). Recently, 
some studies have shown that 5’-adenosine monophosphate-activated protein kinase 
(AMPK) may play a role in regulating PAI-1 expression. Metformin, a potential AMPK 
activator can inhibit PAI-1 expression in the liver (Bergheim et al. 2009). Likewise, 
another AMPK stimulator, adiponectin, can reduce PAI-1. This occurs via activation 
of AMPK in 3T3-L1 Cells (Komiya et al. 2014) and via an influence of AMPK on the 
NFkB pathway in human umbilical vein endothelial cells (HUVEC) (Chen et al. 2017). 
With regard to a potential signaling pathway, fenofibrate can downregulate PAI-1 
gene expression via AMPK-orphan nuclear receptor small heterodimer partner (SHP) 
pathway in hepatocytes (Chanda et al. 2009). An upregulation of SHP by AMPK has 
also been reported for its classic activator metformin in hepatocytes (Kim et al. 2012). 
SHP is an important repressor of many genes (Seol et al. 1996). Thus, AMPK may 
play an important role on the regulation of PAI-1 expression. It is, however, still 
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unknown whether and how AMPK affects PAI-1 production and release in vascular 
cells. 
1.4. 5’-adenosine monophosphate-activated protein kinase  
The virtually ubiquitously expressed 5’-adenosine monophosphate-activated protein 
kinase (AMPK) is one of the most important enzymes for the metabolism of many 
cells like hepatocytes and skeletal muscle cells (Hardie & Ashford 2014; I. Salt & 
Hardie 2017). In 1973, Carlson and colleagues discovered a novel kinase being able 
to phosphorylate acetyl-CoA carboxylase (ACC) and inhibit its function (Carlson & 
Kim 1973). Carling et al. discovered later that the enzyme can be activated by 5’-
adenosine monophosphate (AMP) which led to its denomination as AMPK (Carling et 
al. 1989). AMPK is a serine/threonine kinase in nearly all eukaryotes (Steinberg & 
Kemp 2009a; Hardie & Ashford 2014) serving as an energy sensor involved in 
signaling pathways of anabolism and catabolism (D. Grahame Hardie et al. 2012; 
Carling et al. 2012; Russo et al. 2013). 
AMPK is a heterotrimeric enzyme which is composed of a catalytic alpha (α) subunit 
and two regulatory subunits: beta (β) and gamma (γ) (Steinberg & Kemp 2009a; 
Hardie & Ashford 2014). Each of these subunits has several isoforms. According to 
the literature, α-subunit exists in two isoforms: α1 and α2; the β-subunit also has two 
isoforms (β1 and β2) and there exists three isoforms of the γ-subunit (γ1, γ2 and γ3). 
In mammals, PRKAA1 and PRKAA2 genes encode α1 and α2; PRKAB1 and 
PRKAB2 genes encode β1 and β2; PRKAG1, PRKAG2 and PRKAG3 genes encode 
γ1, γ2 and γ3 respectively (Hardie 2015). The isoforms of each subunits can 
assemble in different combinations to generate 12 different potential AMPK 
complexes (Fiona A. Ross et al. 2016). The isoforms show different expression in 
species and tissues which may have specific roles in cellular metabolic processes 
(Steinberg & Kemp 2009b).  
An AMPK activation is considered to be reflected by the phosphorylation of threonine 
residue (Thr-172) in the α kinase domain (S. A. Hawley et al. 1996) and can further 
be confirmed by phosphorylation of its classic substrate ACC. There are two major 
upstream kinases: liver kinase B1 (LKB1) (Shaw et al. 2004; Woods et al. 2003) and 
calcium/calmodulin-dependent protein kinase kinase (CaMKKβ) (Hawley et al. 2005; 
Woods et al. 2005; Hurley et al. 2005), which catalyze the phosphorylation of Thr-172 
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in AMPK α-kinase domain. Enhanced energy consumption, such as it occurs under 
exercise, or energy depletion like under conditions of glucose deprivation or hypoxia, 
lead to activation of AMPK due to the increase in the ratio of AMP/ATP or ADP/ATP 
(Evans et al. 2016; D Grahame Hardie et al. 2012). AMP binding to γ-subunit of 
AMPK can activate it by three potent mechanisms: (1) by promoting the Thr172 
phosphorylation which is catalyzed by LKB1; (2) by allosteric activation; (3) by 
inhibiting the dephosphorylation of Thr172 by phosphatases (Sakamoto et al. 2004). 
All of them can be inhibited by ATP (Gowans et al. 2013; Fiona A Ross et al. 2016). 
AMPK can also be activated by some hormones, such as adiponectin (Bang et al. 
2017), urocortin2 (Li et al. 2013) and ciliary neurotrophic factor (Watt et al. 2008). At 
the same time, some pharmacological agents are commonly applied to activate 
AMPK in cells or in vivo research. These agents are divided into five classes (I. Salt 
& Hardie 2017). ClassⅠ is the mitochondrial inhibitor such as metformin and 
berberine. ClassⅡ is glycolytic inhibitor such as 2-Deoxyglucose. Both of these 
agents activate AMPK by increasing AMP level (Hawley et al. 2010). Class Ⅲ is one 
type of nucleoside which can be converted to equivalent nucleotide when it is taken 
up by the cells, such as compound 5-aminoimidazole-4-carboxamide ribonucleotide 
(AICAR), and mimicking the AMP function (Corton et al. 1995). Class Ⅳ can be 
converted into AMP analog C2 and activating AMPK (Gomez-Galeno et al. 2010). 
Class Ⅴ includes compounds which can bind with N-lobe on the α sub-unit and β-
CBM of AMPK, then inducing its allosteric change and activation, such as A769662 
(A76) through β-subunit and 2-Chloro-5-[[5-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl] 
methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino] benzoic acid (PT1) through α-
subunit (Xiao et al. 2013; Pang et al. 2008). Compared to so many specific 
pharmacological activators of AMPK, there is still not specific inhibitor available. 
However, dorsomorphin (compound C, CC) is considered to act as relatively specific 
inhibitor of AMPK in research studies (Bain et al. 2007). 
AMPK is considered as a cellular energy sensor, inhibiting anabolic pathways and 
promoting catabolic pathways of cell metabolism (Hardie & Ashford 2014). Its 
activation is involved in the regulation of carbohydrate homeostasis, lipid metabolism, 
protein metabolism, mitochondrial biogenesis, feeding and body weight (Angin et al. 
2016). Therefore, there are substantial research activities focusing on AMPK function 
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in liver (Smith et al. 2016; M. Zhang et al. 2017) and skeletal muscle (Angin et al. 
2016; Koh 2016). At the same time, AMPK has also shown to play important roles in 
some blood cells as well as in the cardiovascular system (I. Salt & Hardie 2017; 
Daskalopoulos et al. 2016). In human and murine organisms, AMPK α1 plays an 
important role in platelet aggregation via VASP, cofilin and cytoskeletal 
reorganization (Onselaer et al. 2014). AMPK α2 shows a key role in platelet αIIbβ3 
integrin signaling via affecting Fyn activity which can lead to clot retraction and 
thrombus stability (Randriamboavonjy et al. 2010). AMPK is present in neutrophils 
and can regulate NADPH oxidase activity in human (Alba et al. 2004). In heart, 
AMPK can be activated by no-flow ischemia in perfused rat hearts and increase of 
heart workload (Kudo et al. 1995; Coven et al. 2003). AMPK can also promote 
anaerobic metabolism and the uptake of glucose by two core enzymes: 
phosphorylating Akt and 6-phosphofructo-2-kinase (PFK2) (Fukuda 2011). It also 
shows the function on the long regulation of cardiac energetic homeostasis via 
peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α) (Patten & 
Arany 2012) and forkhead box O (FoxO) (Kubli & Gustafsson 2014). 
With the ongoing research, AMPK’s roles on regulation of vascular function have 
been elucidated step by step. AMPK-α1 is the major isoform and accounts for the 
majority of total AMPK activity in EC and VSMC (Stahmann et al. 2010; Francoise 
Goirand et al. 2007). AMPK regulates endothelial nitric oxide (NO) via several 
different mechanisms: (1) increasing the activity of eNOS by phosphorylation at its 
Ser633 and Ser1177 (Chen et al. 1999); (2) increasing eNOS association with Hsp90 
(Fujimura et al. 2012); (3) increasing tetrahydrobiopterin (BH4) concentrations via 
GTP cyclohydrolaseI (GTPCH1) (An et al. 2016); and then inducing VSMC 
relaxation, but inhibiting VSMC proliferation and migration, platelet aggregation, 
leukocyte adhesion and proinflammatory signaling (Siragusa et al. 2016). The anti-
inflammatory effects of AMPK in VSMCs and ECs have also been reported. AMPK 
activation can inhibit NFκB activity which is stimulated by TNFα (Cacicedo et al. 
2004) and by IL-6-stimulated Janus kinase-STAT signaling in EC (Rutherford et al. 
2016). As in VSMCs, AMPK activation inhibits NFκB activity and secretion of IL-6 (He 
et al. 2015). 
AMPK activation has also been reported to show a regulatory function on 
vasodilation in different types of arteries (from small artery to aorta) and various 
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species’ vascular beds (Rubin et al. 2005; F Goirand et al. 2007; E. A. Bradley et al. 
2010; Ford & Rush 2011; Ford et al. 2012). Accordingly, treatment with unspecific 
AMPK activators has been shown to reduce arterial blood pressure in vivo (Buhl et al. 
2002; Ford et al. 2012). Our group found by using a pressure myograph system 
(isolated intact arteries under pressure) that AMPK activation modulates intracellular 
calcium homeostasis immediately by large conductance calcium-activated potassium 
(BKca) channel and sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (Holger. 
Schneider et al. 2015). And recently, we also uncovered that AMPK activation dilates 
resistance artery by a novel, Ca2+-independent pathway via the regulation of the G 
and F actin filament dynamics (Schubert et al. 2017). These results suggested that 
AMPK stimulators may not only act as potent anti-diabetic drugs (Gruzman et al. 
2009; Hardie 2013) but also as efficient drugs to treat vascular disease, particularly in 
states with metabolic syndrome (Holger Schneider et al. 2015). The existing literature 
suggests, that the communications between EC and VSMC, via MEJs, can also play 
an important role in modulating blood pressure as well as control of vascular tone. 
However, little is known about the role of AMPK in MEJ and its impact in regulating 
the vessel tone.  
1.5. Hypotheses and aim of the Study 
MEJs are close appositions between EC and VSMC which enable fast and direct 
communication between them, partly via  MEGJ (Straub et al. 2014). MEJs have also 
been described as micro-signaling domains critically regulating calcium handling 
between EC and VSMC and thus, contractility of resistance arteries (Sandow et al. 
2002; Tran et al. 2012). Although some studies offer regulatory pathways on how 
MEJ assemble (Heberlein et al. 2010; Heberlein et al. 2012), little is known about the 
dynamics and regulation of MEJ formation (Straub et al. 2014), in particular in intact 
arteries. Since resistance arteries are the main vessels regulating blood supply to 
match metabolic demands of the tissues (Sarelius & Pohl 2010). The aims and 
hypotheses of this project are following: 
1st aim to develop a method to identify MEJs in intact arteries and to get quantitative 
information about their expression and to correlate it with vascular function. 
2nd aim to test the hypothesis that MEJ formation may be controlled by AMPK.   
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3rd aim to test the hypothesis that AMPK may do so by regulating the expression of 
PAI-1  
Consequently, in this study we try to elucidate the role of the AMPK on MEJ 
formation and function in resistance artery tone, and its potential molecular 
mechanisms. 
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2. Materials and Methods: 
2.1. Buffer solutions and drugs 
Buffer solutions used in this experimental study included (3-
morpholinopropanesulfone acid)-buffered salt solution (MOPS) (manufactured by the 
pharmacy of the Munich University Hospital “Apotheke Klinikum der Universität 
München”, Munich, Germany) (Table 1), phosphate-buffered saline with divalent 
cations buffer (PBS+) (manufactured by the pharmacy of the Munich University 
Hospital “Apotheke Klinikum der Universität München”, Munich, Germany) (Table 2), 
radio immunoprecipitation assay buffer (RIPA buffer) (Table 3), sample lysis buffer 
(Table 4), loading buffer (Table 5), running buffer (Table 6), washing buffer or Tris-
buffered saline with Tween 20 (TBST) (Table 7), transfer buffer (Table 8), and 
blocking buffer which was 5 % bovine serum albumin (BSA) or non-fat milk in TBST. 
The other drugs or agents used in this study are listed in (Table 9). 
Table 1.  Detailed contents of MOPS buffer 
Agents (Dissolved in distilled water) Concentration (mM) 
CaCl2×2H2O 3.0 
MgSO4×7H2O 1.17 
Glucose 5.0 
NaH2PO4×1H2O 1.2 
EDTA 0.02 
MOPS 3.0 
NaCl 145 
KCl 4.7 
Pyruvate 2.0 
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Table 2.  Detailed contents of PBS+ buffer 
Agents (Dissolved in distilled water) Concentration (mM) 
MgSO4×7H20 0.3 
CaCl2×2H2O 0.9 
MgCl2×6H2O 0.3 
NaH2PO4×1H2O 0.8 
KH2PO4 0.4 
NaHCO3 3.6 
KCl 5.4 
NaCl 136.9 
glucose 5.6 
 
 
Table 3.  Detailed contents of RIPA buffer 
Agents (Dissolved in distilled water) Concentration 
NaCl 150 mM 
Tris/HCl 50 mM 
EDTA 5 mM 
Na deoxycholate 0.5 % (w/v : g/100 ml) 
SDS 0.1 % (w/v : g/100 ml) 
Triton X-100 0.1 % (v/v) 
 
 
Table 4.  Detailed contents of sample lysis buffer 
Agents (Dissolved in distilled water) Concentration 
Glycerol 20 % (v/v) 
Tris/HCl 125 mM 
SDS 4% (w/v: g/100 ml) 
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Table 5.  Detailed contents of loading buffer 
Agents (Dissolved in distilled water) Concentration  
SDS 4% (w/v: g/100 ml) 
2-mercaptoethanol 10 % (v/v) 
Glycerol 20 % (v/v) 
Bromophenol blue 0.004 % (w/v: g/100 ml) 
Tris-HCl 125 mM 
 
 
Table 6.  Detailed contents of loading buffer 
Agents (Dissolved in distilled water) Concentration  
SDS 1% (w/v: g/100 ml) 
Glycine 190 mM 
Tris-HCl 25 mM 
 
 
Table 7.  Detailed contents of washing buffer (pH 7.6) (TBST buffer). 
Agents (Dissolved in distilled water) Concentration  
NaCl 150 mM 
Tris 20 mM 
Tween 20 0.1 % (v/v) 
 
 
Table 8. Detailed contents of transfer buffer. 
Agents (Dissolved in distilled water) Concentration 
Methanol 20 % (v/v) 
Tris 25 mM 
Glycine 190 mM 
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Table 9. Drugs and chemicals used in the experiments 
Drugs or Agents Company 
cheluminate-HRP PicoDetect solution 
A and B (A3417, 1200 A and B) 
PanReac AppliChem 
(Gatersleben, Germany) 
Non-fat dried milk powder 
(A0830,0500) 
 
Albumin fraction V(A1391, 0100)  
Antipain  
Bromophenol blue  
DMSO  
KCl  
MgSO4  
Na4P2O7  
NaCl  
SDS  
Tris  
KH2PO4  
CaCl2  
EDTA  
Na3VO4 Alexis Corporation (Lausen, Switzerland) 
Manganese (II) chloride tetrahydrate Sigma Aldrich (Deisenhofen, Germany) 
L-NAME(N5501)  
Indomethacine (17378)  
Acetycholine (Ach)  
Heptanol  
Meflumic acid  
Porcine smooth muscle cell growth 
medium (P311_500) 
 
NaOH Merck Millipore (Billerica, MA, USA) 
Ethanol  
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NaF  
Norepinephine Aventis Pharma (Frankfurt, Germany) 
A769662 Tocris (Bristol, UK) 
compound C  
Aprotinin (A162.1) Carl Roth (Bavaria, Germany) 
Leupeptin (CN33.1)  
Distilled water (Aqua ad iniectabilia) B/BRAUN (Melsungen,Germany) 
Endothelial cell growth medium Promocell (Heidelberg, Germanz) 
 
2.2. Probes and Antibodies 
The probes and antibodies which were used in this experimental study are showed in 
the (Table 10). 
Table 10. Probes or antibodies 
Probes and Antibodies Company 
Calcein Red-Orange-AM 
Thermo Fisher Scientific (Waltham, MA, 
USA ) 
ER-Tracker™ Green 
(BODIPY® FL Glibenclamide) 
 
Glycine  
Phalloidin-Alexa546  
MPPSense645 PerkinElmer (Waltham, MA, USA) 
Fura2-AM LifeTechnologies (Carlsbad, CA, USA) 
Active PAI-1 MolecularInnovations ( Novi, USA) 
anti-Cx37 antibody Α Diagnostics ( San Antonio, USA) 
anti-Cx43 antibody  
Anti-AMPKα1/2 antibody Abcam (Cambridge, UK) 
Anti-phospho-AMPKα1/2 antibody Cell Signaling (Danvers, MA, USA) 
Anti-phospho-ACC antibody  
Anti-SHP antibody(sc-271511) Santa Cruz (Heidelberg, Germany) 
Anti-PAI-1antibody(sc-9 5297)    
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Anti-GAPDH antibody Merck Millipore (Billerica, MA, USA) 
KAPA mouse genotyping Kits Sigma Aldrich (Deisenhofen, Germany) 
 
2.3. Animals, isolation and cannulation of resistance-type arteries 
All animal care and experimental protocols were conducted in accordance with 
German federal animal protection laws. C57BL6/N mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany). LifeAct mice were kindly provided by 
Reinhard Fässler (MPI of Biochemistry, Martinsried). AMPKα-1 and α-2 knockout 
(KO) and their respective littermate wildtype (WT) mice were from the Jackson 
Laboratory (USA). The mice were killed by cervical dislocation, the mesentery or the 
legs of the mouse were removed and pinned onto a silicon-coated petri dish for 
subsequent vessel dissection (Figure 2A and 3A). Fine dissection of mesenteric or 
muscle (saphenous) arteries was performed in ice-cold MOPS buffer. For mesenteric 
arteries, first order to fourth order branches of the superior mesenteric artery were 
dissected (Figure 2B). For muscle arteries, the whole saphenous artery was 
dissected (Figure 3B). Isolated arteries were then cannulated as described before 
(Steffen-Sebastian Bolz et al. 1999) (Figure 4). 
Briefly, the glass pipettes (GB100F-10:0.58*1.00*100 mm, SCIENCE PRODUCTS 
GmbH) were pulled into two equally pointed cannula with a laser-based micropipette 
puller (P-2000, SUTTER INSTRUMENTS CO., Novato, USA), then they were fixed 
on the setups on both sides via a screw. Both cannulas were then connected to the 
three-way stopcock via a silicone tubing (TYGON® 3350, Pro Liquid). One cannula 
became the inlet; the other became the outlet of the vessel. The inlet was connected 
to a tube (original perfusor line) (B/Braun, Germany) stuck onto a 20 ml syringe 
(B/BRAUN, Germany) and filled with MOPS. Secondly, the proximal end of artery 
was mounted onto the inlet cannula and secured with the help of two knots made 
from 10-0 ethilon sutures (Georgia, USA). Then the lumen of artery was flushed with 
MOPS to remove the remaining blood. Afterwards, the distal end of the artery was 
mounted onto the outlet pipette by the way as mentioned above, followed by a test 
for leakage (leaving the artery first at 60 mmHg pressure and then closing both 3-way 
stopcocks whilst observing for possible collapse; then the stopcocks were opened 
again whilst watching out for any re-expansion of the vessel. Leaky arteries were 
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discarded. Lastly, the artery was stretched gently in axial direction at 60 mmHg 
transmural pressure until no more lateral buckling occurred.  
When used for experiments with subsequent protein extraction, all mesenteric 
arteries were dissected and divided into equal parts as required by the number of 
experimental groups.  
 
 
 
Figure 2. Preparation of mesenteric arteries. 
In this image, the intestine was left in situ to clarify the anatomic relations to the supplying 
vessels. (A): The whole mesentery supplying the small intestine was dissected sharply from 
intestine, then it was pinned onto a silicon-coated petri dish with the fatty-tissue segments 
containing the vessels spread out in a the fan-like shape. (B): The adjacent vein, fatty and 
connective tissue were carefully removed until the desired order branch had been totally 
cleared. Vessels of first (I) to fourth (IV) order were used in experiments requiring protein 
extraction. Vessels of second (II) to third (III) order were used in the other experiments in this 
project. Subsequently, the arteries were transferred to an organ bath or a cell culture dish as 
outlined below. 
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Figure 3. Preparation of saphenous artery. 
For functional studies (Ach DRC), saphenous arteries with a maximal outer diameter of 
roughly 350 µm were prepared. (A): The skin was removed from the groin to the paws and 
the leg was then separated from the rest of the body. Afterwards, it was pinned onto a 
silicon-coated petri dish with cannulae. (B): The adjacent vein, nerve as well as attached 
fatty and connective tissues were carefully removed by sharp dissection, and the isolated 
saphenous artery was transferred to an organ bath for subsequent experiments. 
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Figure 4. Pressure myograph system (Isobaric arteriography). 
The freshly isolated vessel was fixed by 10-0 sutures to glass pipettes mounted on holders 
whose position could be controlled by micromanipulators. Firstly, artery was mounted on 
both sides and flushed free of blood with MOPS solution. Thereafter, the artery was 
stretched to in situ length and exposed to a hydrostatic pressure of 60 mmHg via the inlet 
whereas the outlet three-way stopcock remained closed. (A): Overview of the pressure 
myograph system. The inlet syringe with MOPS was fixed at a height corresponding to a 
hydrostatic pressure of 60 mmHg during the experiments. (B): The whole setup with the 
mounted artery. (C): Magnified image of the living artery at physiological pressure. 
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2.4. Recording of MEJ dynamics and live imaging. 
Arteries from LifeAct-GFP mice were isolated, cannulated and pressurized at 
60mmHg. Respective live-dyes were added to the cells via the intra-luminal route 
(infused through the silicone tubings, Calcein-AM red orange [1µM], Bodipy-
Gibenclamide ER-Tracker [1 µM]) or via the abluminal route (Added to the organ 
chamber, Alexa633 [0.2 µM]). After thorough washing with PBS+, transmural image 
stacks as time-lapse recordings at the same area or for quantification purposes at 
different areas along the vessel length were obtained in the respective vessels using 
a Leica TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany) 
(Figure 5) or two photon excitation fluorescence microscope(Leica, Germany). 
Images were analyzed in a blinded manner with Fiji ImageJ Software (ImageJ 1.x) 
(Schneider et al. 2012).  
 
Figure 5. Setup under the confocal microscope. 
The mouse arteries and immunofluorescence images were acquired with the SP5 confocal 
microscope (Leica microsystems, Wetzlar, Germany). (A and B): The setup with the 
mounted and pressurized artery was fixed on the confocal microscope. (C): The overview of 
the confocal microscope. 
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2.5. Immunofluorescence. 
Cannulated and pressurized arteries from C57BL6/N mice were fixed for one hour 
with 3.7% formaldehyde. Thereafter, the vessels were intra- and extra-luminally 
permeabilized for 30 minutes with 0.5% Triton X-100, blocked with 1% BSA in 
phosphate-buffered saline with divalent cations (PBS+) followed by the addition of 
primary antibodies overnight at room temperature (PAI-1, AMPKα1/2, Cx37, Cx43, 
Cortactin and MMP14). Then, they were incubated for two hours with the respective 
secondary antibodies coupled to fluorescent dyes. Finally, images were acquired with 
a Leica TCS SP5 confocal microscope (Leica Microsystems) (Figure 5). Images 
were analyzed with the help of Fiji Imaging software (ImageJ Version 5.2) (Schneider 
et al. 2012). 
2.6. Assessment of heterocellular dye transfer. 
In another set of experiments with the cannulated and pressurized arteries, MOPS 
solution containing calcein-AM (1 µM) was perfused through the artery lumen for 10 
min to enable the selective loading of dye into endothelial cells. Afterwards, the 
lumen was flushed with MOPS buffer and the artery was incubated from the 
abluminal side with Alexa 633 for the visualization of the IEL (Internal elastic lamina). 
The time of calcein dye loading was kept constant at 20 min in all experiments. 
Meflumic acid (100 µM) and heptanol (250 µM) were used to block gap junctions. 
They were added to the organ chamber 30 min prior to calcein loading, and remained 
present during the loading and imaging periods. Vessel Images were obtained using 
a Leica TCS SP5 confocal microscope (Leica Microsystems). Arteries were excited at 
543 nm for calcein-AM red-orange and at 633 nm for Alexa 633 imaging. The 
emission filters were set at 550-600 nm and 640-660 nm, respectively. Fluorescence 
was excited and registered through a 60x water immersion objective using the same 
laser, pinhole (0.5 AU), photomultiplier and HyD-detector settings in all experiments. 
Z-stacks through the wall of the artery were obtained in 0.35 µm steps (Leica 
Application Suite X software Version: 2.0).  
2.7. Calcein spreading and diffusion. 
Calcein spreading and diffusion was determined by using fluorescence recovery after 
photobleaching (FRAP) technique. A pressurized artery was loaded luminally with 
calcein-AM red-orange (1 µM) in calcium-free MOPS solution for 20 min which 
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remained in the lumen while imaging was performed. A 40x12 µm area in the VSMC 
layer with a typical calcein MEJ structure was recorded and afterwards bleached for 5 
second with 100 % intensity of the 534 nm laser. Afterwards, the diffusion of the 
calcein signal in different regions of interests (ROI) in the VSMC over time (30 min) 
was recorded. 
2.8. Image analysis. 
For the analysis of MEJs and IEL hole count, EC-VSMC calcein transfer, MMPsense 
signal quantification, Alexa633 IEL thickness quantification in intact arteries, Fiji 
ImageJ software was adopted. MEJs in muscle and mesenteric arteries were 
quantified by counting bright calcein-AM red orange stainings in IEL holes. IEL holes 
were quantified by constructing a Fiji ImageJ Plugin. Shortly, raw images were pre-
processed (unsharp masking and bandpass filter to compensate for inhomogeneous 
staining intensities and slightly oblique IEL level), a grey value threshold applied and 
fenestrations with a minimal diameter were analyzed: 
Run("Unsharp Mask...", "radius=5 mask=0.60 stack"); 
Run("Enhance Contrast...", "saturated=5"); 
Run("Bandpass Filter...", "filter_large=40 filter_small=3 suppress=None tolerance=5 
autoscale saturate"); 
getRawStatistics(nPixels, mean, min, max); 
t2 = 0.3*mean; 
t1 = min; 
setThreshold(t1, t2); 
setOption("BlackBackground", false); 
Run("Convert to Mask"); 
Run("Analyze Particles...", "size=1-Infinity show=[Overlay Masks] display clear 
include summarize"); 
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2.9. Acetylcholine (Ach) dose response curves. 
The saphenous arteries were treated as published before (S.-S. Bolz et al. 1999). 
Briefly, the prepared arteries were mounted on the setups and pressurized at 60 
mmHg (Figure 5). Then the setup was transported to the stage of a modified inverted 
microscope (Diaphot 300, Nikon, Düsseldorf, Germany) equipped with a 20x lens (D-
APO 20 UV / 340, Olympus) and a video camera (Watec, WAT-902B) (Figure 6). 
The organ bath temperature was slowly raised to 37 °C. The arteries were loaded 
with the Ca2+ indicator Fura2-AM (2 μM, LifeTechnologies, Carlsbad, CA, USA) in an 
incubation period of 90 min. Before the Ach dose response curve (DRC), the arteries 
were pre-incubated with 30 µM L-NAME (Nω-nitro-l-arginine methyl ester) and 30 μM 
indomethacine for 45 min. The measured Fura2 signals were corrected for 
background fluorescence (as measured at the end of each experiment after 
quenching with 8 mM MnCl2). Simultaneously with the measurement of cytosolic Ca
2+ 
concentrations [Ca2+]i, vascular outer diameters were recorded by video-microscopy 
and displayed with the help of BVA software (Hasotec, Rostock, Germany) (Figure 6)   
(Schubert et al. 2017). Increasing concentrations of Ach (3 nM or 10 nM-3 µM) were 
added for 2-4 min after pre-constriction of the arteries with norepinephrine (NE) (1 
µM). Peak Ach-dilations and concomitant Ca2+-decreases were used for 
quantification. 
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Figure 6. The calcium measuring and diameter registration system. 
The heating system allowed to keep the pressurized arteries at a constant temperature of 37 
°C. A detailed description of the total setup has been published earlier in doctoral dissertation 
from our institution (Kreutz 2013). Briefly, the illumination unit generated monochromatic light 
of the wavelengths 340 nm and 380 nm for the excitation of the vessel loaded with Fura-2. 
The resulting emission wavelength (510 nm) was transmitted to a photomultiplier. The 
excitation wavelengths were excluded from the analysis with the help of a bandpass filter. 
For the diameter registration, the vessel was illuminated by red light (to minimize interference 
with the simultaneous calcium measurement) which was transmitted to a CCD camera. Both 
signals were digitalized in a Bryte box and fed to a personal computer where they could be 
simultaneously displayed and recorded. These signals were exported to Microsoft Excel to 
subtract the background fluorescence. In parallel to the digital records, the artery image was 
displayed live on a second computer directly connected to the camera.  
2.10. Protein isolation from intact arteries. 
For the detection of PAI-1, SHP, GAPDH and total AMPK in arteries from AMPK α1 
and α2 knockout (KO) and wild type (WT) mice were used (the respective littermate 
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WT for each strain). The mice were sacrificed by cervical dislocation and the α1 
genotype was checked by examining the spleen. Afterwards, the whole arteries of a 
murine mesenterium were isolated, cannulated on one side, flushed free from 
intraluminal blood, divided into two roughly equal parts. Afterwards, the samples were 
snap-frozen in liquid nitrogen. Concerning the arteries from C57BL6/N (male mice, 
Charles River, Sulzfeld, Germany), the whole mesenteric arteries (MA) were isolated, 
and flushed free from intraluminal blood; secondly, the arterial tree was divided into 
three or four roughly equal parts; Subsequently, the arteries were transferred to a cell 
culture dish filled with MOPS buffer and incubated them for 15 min at 37 °C; thirdly, 
the arteries were treated with DMSO (0.01 %), 10 µM A76, 10 µM A76 plus 10 µM 
CC or 10 µM CC (all in MOPS buffer) at 37 °C for 1 hour, respectively. At the end of 
the experiment, the arteries were harvested by snap-freezing in liquid nitrogen. The 
arterial protein was extracted as previously described (Holger Schneider et al. 2015). 
Briefly, if half of the MA was used, the sample was minced thoroughly in a starting 
volume of with 20 µl lysis buffer in glass mortar, the pestle was minced thoroughly, 
rinsed with another 10 µl lysis buffer and the sample was centrifuged. This procedure 
was repeated until there were 50 µl lysis buffer in the mortar; if single arteries were 
used, the starting volume was 10 µl, rinsing volume remained 10 µl and the final 
volume was 30 µl, Then the suspension was pipetted up and down until only foam 
was left in the mortar. The foam was then transferred to a new reaction vial. 
Afterwards, the foam was spun down at 18000 revolutions per minute (rpm) and 4 °C 
for 15 min; at the end, the supernatant containing the protein was transferred to a 
new vial and stored at -80 °C until a conventional Western Blot (WB) was performed. 
2.11. Cell culture, siRNA transfection and protein harvest. 
Porcine coronary artery smooth muscle cells (PCASMCs, Sigma Aldrich, 
Deisenhofen, Germany) and human umbilical vein smooth muscle cells (HUVSMCs) 
were cultured according to the provider’s instructions in a humidified chamber with 
ambient conditions of 5 % CO2 and 95 % O2. Porcine smooth muscle cell growth 
medium was applied for PCASMC culture. AMPK knockdown: siRNA against both 
AMPK α-subunits (sc-45312) or control siRNA (sc-28 37007) both Santa Cruz, 
Heidelberg, Germany) was transfected into PCASMC cells using Lipofectamine 
RNAiMAX Transfection Reagent (ThermoFisher, Waltham, MA, USA) according to 
the manufacturer’s protocol. Cells grown in six well plates were transfected in Opti 
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MEM medium for 4 hours. Afterwards, 4 ml culture medium was added on top. The 
culture medium included 1 % penicillin-streptomycin solution (10000 U penicillin and 
10 mg streptomycin/ml). After 3 days of culture, protein was harvested by removing 
the medium and adding 150 μl of ice cold RIPA buffer with protease and 
phosphatase inhibitors in each well. The retrieved solution was the stored at -80 °C 
until subjected to conventional WB. The human umbilical vein endothelial cells 
(HUVECs) were purchased from Promocell and were cultured with specific culture 
medium (Medium 199 (Gibco, 31150-022) supplemented with 20 % NBCS and 1 % 
penicillin-streptomycin (10000 U penicillin and 10 mg streptomycin/ml) and 
substituted with endothelial cell growth medium (Promocell, C22010 at a 1:2 
dilution)). Like in PCASMCs, the siRNA against both AMPK α-subunits (sc-45312) or 
control siRNA was transfected into HUVECs using Lipofectamine 2000 transfection 
reagent according to the following protocol (6 well plate): cells were grown to 70-80 
% confluency, the medium was removed and cells were washed one with PBS, opti 
MEM medium was added (700 µl per well) together with the siRNA mixture. Then 
HUVECs were incubated for 6 hours, the transfection reagents were removed and 
HUVEC medium was applied onto the cells (medium199: endothelial cell growth 
medium=1:1) 3 ml for each well. After 2 days of culture, protein was harvested as 
described for HUVSMC. The brief harvesting protocol: cells were scraped from the 
bottom of the culture dish with a scraper; the lysate was transferred into a reaction 
vial (1.5 ml Eppendorf reaction vial); the vial with the cell lysate was vigorously 
vortexed for 30 sec to 1 min, then it was incubated on ice for 10 min; this procedure 
was repeated 5 times. Afterwards, the sample was stored at -80 °C (dry ice) for 20 
min. Then, the sample was centrifuged at 18000 rpm and 4 °C for 15 min; at the end, 
the supernatant containing the protein was transferred to a new vial, and stored at -
80 °C until conventional WB was performed. 
2.12. Western blot. 
The harvested proteins were separated via sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) in Mini-PROTEAN Tetra system (BIO-RAD, USA) 
via a constant current of 25 milliamperes (mA) per gel for 1 hour, transferred onto a 
0.2 µm PVDF membrane (BIO-RAD, USA) in a Trans-blot Turbo Transfer system 
(BIO-RAD, USA)  via constant current of 2.5 A for 7 min, blocked in 5 % milk powder 
in TBST for 1 hour, then incubated with the primary antibody in 5 % BSA in TBST 
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buffer (anti-total-AMPK (α1 and α2) antibody dilution 1:1000, anti-phosphor-AMPK 
(α1 and α2 (T172)) antibody dilution 1:1000, anti-PAI-1 antibody dilution 1:200, anti-
SHP antibody dilution 1:100, anti-phospho-ACC antibody dilution 1:1000 and anti-
GAPDH antibody dilution 1:10000). The incubation period was 12 or 36 hours on a 
shaker at 4 °C. Afterwards, the membranes were washed with TBST buffer for 4 
times with gentle shaking, each time for 5 min, and then incubated with the 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibody 
(dilution 1:1000) for 1 hour. After this, the membranes were again washed with TBST 
buffer for 4 times, each time for 5 min. Finally, bound secondary antibody was 
visualized by HRP-mediated luminol oxidation (AppliChem, Darmstadt, Germany) 
which was detected with a CCD camera. The images were analyzed with Fiji ImageJ 
Software and the band intensities were quantified with Image Studio software (LI-
COR Biosciences) (Miller 2010). 
2.13. Mouse genotyping via PCR. 
The genotypes of all mice of the AMPK α1 and α2 strains was determined by PCR 
according to the KAPA Mouse Genotyping Kit (KAPABIOSYSTEMS 2016) in 
duplicate (ear sample after birth and tail plus ear after sacrifice). 
DNA extraction: The detailed contents of DNA extraction buffer and its protocol are 
shown in Table 11 and 12.The samples were centrifuged briefly to pellet cellular 
debris and the extract was diluted 10-fold with 10 mM Tris-HCl. Then the samples 
were stored at -20 °C. The PCR master mix was prepared as follows: PCR-grade 
water 25 µl, 2 KAPA2G fast genotyping Mix (Containing DNA polymerase for fast 
PCR, MgCl2 (1.5 mM), dNTPs(0.2 mM)) with dye 12.5 µl, forward primer 1.25 µl 
(Final concentration 0.5 µM), reverse primer 1.25 µl (Final concentration 0.5 µM) and 
1 µl of prepared DNA extract. The protocol for PCR is shown in Table 13. After PCR, 
samples were separated by agarose gel electrophoresis. AMPK α1 KO forward 
primer: 5´CCT TCC TGA AAT GAC TTC TGG 3´, AMPK α1 KO reverse primer: 
5´GGG CTG CAG GAA TTC GAT ATC 3´, AMPK α1 WT forward primer: 5´AGC 
CGA CTT TGG TAA GCA TG 3´, AMPK α1 WT reverse primer: 5´CCC ACT TTC 
CAT TTT CTC CA 3´.AMPK2_neo_up primer: 5´GCT TAG CAC GTT ACC CTG GAT 
GG 3´, AMPK2_neo_down primer: 5´ GTT ATC AGC CCA ACT AAT TAC AC 3´. 
 
44 
 
 
 
Table 11. Detailed contents of DNA extraction buffer  
Component Per 100 µL reaction (µL) 
PCR-grade water 88 
10X KAPA Express Extract Buffer 10  
1 U/µL KAPA Express Extract Enzyme 2 
 
Table 12.  DNA extraction protocol  
Step Temperature(°C) Duration(min) 
Lysis Step 75 10 
Enzyme inactivation 95 5 
 
Table 13.  PCR cycle protocol 
Step Temperature(°C) Duration Cycles 
Initial denaturation 95 3 min 1 
Denaturation 95 15 s  
Annealing 60 15 s 33 
Extension 72 15 s 
 
 
Final extension 72 7 min 1 
Afterwards, the this system was cooled to 4°C. 
2.14. Statistics. 
For data presentation and computation of statistical tests SigmaPlot (Systat, Erkrath, 
Germany) was applied. Statistical tests comprised parametric tests, i.e. one way 
ANOVA, t-test, and paired t-test when the data were normally distributed. Mann-
Whitney Rank Sum Test was used when the data were not normally distributed. Two 
way ANOVA was used in the compare of acetylcholine response curve in different 
artery. For descriptive reasons, all values are presented as means ± standard error of 
the mean (SEM). Differences were considered statistically significant when the alpha 
error probability was < 0.05.   
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3. Results 
3.1. Observation of actin-rich circular and cone-like structures in mesenteric 
arteries. 
In the endothelium of isolated and pressurized mesenteric arteries of LifeAct-GFP 
mice, we observed structures which were characterized by <1µm cone-like actin core 
surrounded by a virtually actin free zone of about 7 µm in radius around the cone 
except for thin intersection which gave the structure an appearance of a wheel with 
hub and spokes (“wheel like structure”, WLS). All of them being exclusively located in 
the area of holes in the IEL (Figure 7A). Actin staining with phalloidin and, 
surprisingly, also calcein red-orange stained the exactly same pattern or WLS in 
mesenteric arteries from C57BL6/N mice (Figure 8 A). Calcein stain was more 
intense than the LifeAct-GFP signal. Due to the calcein loading from the endothelial 
side calcein stain was pronounced in ECs and less intense in adjacent VSMCs, so 
that MEJ structures on the endothelial side were easier to detect. All WLS stained 
with calcein in the endothelial layer had a corresponding actin hub when stained 
simultaneously with phalloidin (n=3). Further structural characteristics of the WLS in 
LifeAct mice are listed in (Table 11). WLS were exclusively located in holes of the 
IEL, the only areas where endothelial cells and smooth muscle cells can get direct 
contact (Figure 7A, Figure 8 A and C). We found that there were 1.86 ± 0.17 WLS 
and 5.35 ± 0.5 IEL holes per 10³*µm² IEL in mouse mesenteric arteries (>250 µm in 
size, n=10) (Figure 8B), and so about 35 % ± 1.8 % of IEL holes exhibited WLS 
(Figure 8C). 
 
46 
 
 
Figure 7. Localization of MEJs and Podosomes in intact arteries of LifeAct mouse. 
Mesenteric arteries from LifeAct-GFP mice were cannulated, pressurized, and co-stained 
with cortactin (red) and Alexa 633 (grey, for IEL). Images were taken using a Leica TCS SP5 
confocal microscope (Leica Microsystems). (A):  Wheel-like or cone-like LifeAct structures 
were observed always located in IEL holes and are negative for cortactin. These structures 
were identified as MEJs (marked by arrow). (B): Round actin containing structures was also 
observed in LifeAct vessels. These structures were positive for cortactin and were not 
located in IEL holes, suggesting that these structure represented podosome rosettes 
(arrows). Scale bar is 10 µm. 
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Figure 8. Calcein staining co-localizes with the actin signal around MEJs. 
The wheel like structures as observed in LifeAct-GFP mouse arteries could also be detected 
when using the F-actin stain phalloidin in permeabilized  vessels. Surprisingly, after loading 
the intact endothelium with calcein red-orange AM, the same structures could be identified 
which allowed long term observation of the dynamics of the structures. (A): Images of 
vessels treated with the different stains. (B): Quantification of the number of WLS and holes 
in IEL. There were 1.86 ± 0.17 WLS and 5.35 ± 0.5 IEL holes in 10³*µm² IEL (n = 10). (C): 
100% of the WLS were located in the area of holes whereas 35 % ± 1.8 % of IEL holes were 
“filled” with MEJs in mesenteric arteries (n = 10). Scale bar is 20 µm. 
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Table 14. The comparison of characteristics between WLS and ring-like 
structures (RLS). 
 WLS RLS 
Cortactin positive Staining 
MMP14  positive staining 
Cx37/ Cx43 postive staining 
No 
No 
Yes 
Yes 
Yes 
No 
Actin impression on the 
smooth muscular side 
Low ~ 1μm Flat: a few hundred nm 
Endothelial-sided actin 
structure 
Wheel-shaped/ Star-shaped Circular 
Position to the IEL hole Central On the edge 
Position to overlying muscle 
cells 
Regularly between two 
muscle cells 
More often under a single 
muscle cell 
3.2. Characterization of WLS. 
To distinguish these structures, from other actin rich structures, so called 
podosomes, some markers for podosomes where studied. The WLS were not 
positive for a co-staining with cortactin (Markers for Podosome) (Figure 8A) though 
morphologically different, larger ring like structures stained positive for cortactin and 
MMP-14 (Figure 7B and Figure 9). Those were not always located near holes of the 
IEL (Figure 9). The WLS stained positive for Cx43 (95 % ± 2.5 %), PAI-1 (100 %) 
and partially for Cx37 (46.6 % ± 2.3 %), proteins that have been described to be 
enriched in MEJ (Figures 10, 11). WLS were therefore considered to represent cell 
(EC and VSM) protrusions which corresponded through holes of the IEL containing 
connexins known to be enriched in myoendothelial gap junctions (MEGJs). We 
therefore defined these WLS as MEJs and this term will be used further in the results 
section. The endothelial wheel-like structure was enhanced by staining with calcein 
red-orange (Figure 8A, Figure 11).  
To further support the conclusion that WLS contained gap junctions, gap junction 
inhibitors were used. Incubation of pressurized arteries with meflumic acid (100 µM) 
and heptanol (250 µM) reduced the staining of vascular smooth muscle cells with the 
gap junction permeable dye calcein which was loaded from the luminal side by 52.8 
%  (n=4) (Figure 13). To analyze further, whether calcein passed through MEJ one 
additional experiment was applied in which calcein was bleached and the recovery of 
the calcein signal in smooth muscle was studied in in regions of interest with different 
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distances from a MEJ. The results indicated that recovery of the calcein signal was 
faster in regions near the MEJ (Figure 14). These were not continued since 
bleaching could not be restricted exclusively to smooth muscle cells. 
 
 
Figure 9. Circular structures are podosome rosettes (PRs). 
To identify and localize PRs in artery, C57BL6/N mice were used. The pressurized arteries 
were stained with PR markers (cortactin and MMP14). Results showed that the circular 
structures were positive for cortactin and MMP14 while the structures were not in the IEL 
holes (as shown by arrow), suggesting that they were PRs. Scale bar is 20 µm. 
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Figure 10. Cx37 and 43 is enhanced on WLS of intact mesenteric arteries. 
Typical example of a vessel co-stained with Phalloidin (Mimicking the LifeAct structure), 
Cx37 and Cx43. The image shows an enhance Cx37 and Cx43 signal in the area of the 
WLS, suggesting close enrichment of Cx37 and Cx43 in this area. Scale bar is 5 µm. 
 
 
Figure 11. PAI-1 signal is enhanced on WLS of intact mesenteric arteries. 
Typical example of a vessel co-stained with calcein and PAI-1. The image shows an 
enhanced PAI-1 signal in the area of the WLS, suggesting enrichment of PAI-1 in this area. 
Scale bar is 5µm. 
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Figure 12. Gap junction inhibition blunts heterocellular dye transfer from ECs to 
VSMC. 
Mesenteric arteries from C57BL6/N mice were incubated with the gap junction blockers 
meflumic acid (MA, 100µM) and heptanol (250µM) before calcein loading from the luminal 
side was performed. Under these conditions the calcein staining of smooth muscle cells 
/vertical cells structures) was reduced, indicating that calcein was being reaching smooth 
muscle mainly through gap junctions. After gap junction inhibition, the heterocellular dye 
transfer was reduced. Compared to the control, the treated artery decreased heterocellular 
dye transfer by 52.8%. (A): Representative images of muscle staining with calcein Red-
Orange with and without gap junction blockers; (B): Quantification of the ratio of VSM to EC 
intensity signal with and without gap junction blockade (t-test (Shapiro-Wilk), *p<0.05, n = 4). 
Scale bar is 20 µm. 
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Figure 13. Calcein recovery in smooth muscle after bleaching starts from the WLS. 
To confirm that the WLS were the sites of MEJ dye transfer, the calcein signal was bleached 
and the recovery of the calcein signal was analyzed in different ROIs at various distances 
from a WLS. The calcein signal increased first at the WLS (green), followed by areas 
adjacent to the WLS (light blue) and areas in intermittent distance to the WLS (violet, purple, 
orange and yellow) before it finally reached the area farthest away from a WLS (blue). The 
red arrow shows the position of WLS or MEJ. The diffusion velocity of the calcein signal was 
with 0.6 µm/min comparable to data published before (Bathany et al. 2011).  
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3.3. The dark area around the actin cone of WLS represents endoplasmic 
reticulum (ER). 
We asked the question what the dark area as observed with LifeAct/phalloidin as well 
as calcein staining could represent (Figure 7A and Figure 8A). The ER has been 
shown to be expressed around MEJ structures (Tran et al. 2012). Consequently, we 
tested if ER is enriched around MEJ using the ER specific stain ER-Tracker™Green 
(ER-Bodipy) (n=3). ER staining showed indeed that ER was enriched in the dark area 
(Figure 14).  The density of the ER stain in WLS area was significantly higher than in 
other areas (t-test, p<0.05, n=3). 
 
Figure 14. ER was enriched around the actin core of a WLS in intact artery. 
Mesenteric arteries were co-stained with ER-Bodipy (ER Tracker) (green), calcein (red) and 
Alexa 633 (grey). WLS were compared with remote areas randomly selected. (A): 
Representative images of a vessel with simultaneous ER-Bodipy and calcein staining, 
showing three independent WLS and non-WLS areas 1-3. (B): Magnified images of these 
areas demonstrating that the ER-Bodipy signal was higher in WLS as compared to non-WLS 
areas as quantified in (C) (Normality Test (Shapiro-Wilk), *p<0.05, n = 3). (D): Magnified 
image of a WLS showing intense ER staining around the actin core.  Values are normalized 
to random area ER Bodipy signal. 
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3.4. AMPK modulated MEJ dynamics. 
Lately, we reported that AMPK is important for the control of actin dynamics in the 
vascular smooth muscle of small vessels. We also have shown that AMPK can 
stimulate the SERCA. In view of these effects we studied a potential role on 
expression and dynamics of MEJ. To this end, we incubated cannulated LifeAct 
mouse arteries with either compound C (CC; 10 µM), an inhibitor of the AMPK, or 
A769662 (A76; 10µM), an activator of the AMPK, or DMSO as the vehicle control. 
The MEJ dynamics were monitored under confocal microscopy (Figure 15). After 4 
hour incubation, the number of MEJs was found to be augmented in CC treated 
arteries as compared with the sham treated time controls (Figure 16). In CC treated 
vessels we found that the number of IEL holes “filled” with a WLS increased to 51.0 
% ± 7.1 % in vessels treated with CC as compared with 35.2 % ± 6.2 % in vessels 
treated with DMSO (n=3). The number of IEL holes was not changed in arteries 
treated with the AMPK-inhibitor CC. The increase in MEJ numbers went along with 
better ACh-mediated dilation (Figure 17B). A76 incubation had no effect on MEJs 
density as compared to time controls (39.1 % ± 3.3 % n=3) within the observation 
period (Figure 17A). A significant decrease of heterocellular calcein transfer was 
observed when arteries treated with CC (Figure 18). 
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Figure 15. Development of new WLS in a mesenteric artery of a LifeAct mouse after CC 
incubation. 
A mesenteric artery of a LifeAct-GFP mouse was incubated with AMPK inhibitor CC (10 µM) 
and a time lapse series over 150 minutes recorded. White arrows indicate already existing 
actin bridges, red arrow depict newly appearing actin bridges during the subsequent 
observation periods. Scale bar is 10 µm. 
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Figure 16. AMPK inhibition boosted MEJ development compared to time control. 
Two examples of mesenteric arteries of LifeAct-GFP mice were incubated with CC (10µM) or 
DMSO as vehicle control for 60 minutes. (A): The box depicts areas where actin bridge areas 
disappear or newly developing of the actin bridge. (B): Change of the number actin bridges 
detectable per unit area after a 60 minutes’ observation period (Normality Test (Shapiro-
Wilk), p<0.05, n = 3). Scale bar is 10µm. 
 
Figure 17. Inhibition of AMPK increased the fraction of holes filled by WLS and 
enhanced Ach-mediated dilation of the artery. 
Mesenteric and muscle arteries from C57BL6/N mice were incubated with A76 10µm, CC 10 
µm or DMSO as control for 3 hours. (A): CC significantly increased the fraction of holes filled 
with WLS compared to time control and A76 (One Way ANOVA, *p < 0.05 CC vs. A76, **p < 
0.05 CC vs. time ctrl, n=10 or 4). (B): Saphenous arteries showed a significant left shift of the 
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ACh DRC in CC treated arteries compared to A76 treated arteries (Two Way ANOVA, n.s p > 
0.05, n = 3).  
 
Figure 18. Inhibition of AMPK decreased calcein transfer from EC to VSMC, and 
enhanced formation of vesicles along nuclei. 
Mesenteric arteries from C57BL6/N mice were incubated with A76 10µM, CC 15 µM or 
DMSO as control for 4 hours, and then stained with calcein Red-Orange. Compared to the 
control, CC treatment decreased heterocellular dye transfer. (A) Representative images with 
and without CC incubation (B): CC incubation significantly reduced the dye transfer from EC 
to VSMC compared to other two groups (One Way ANOVA, *p<0.05 CC vs. Ctrl or A76, 
n=4). Scale bar is 20µm. 
3.5. AMPK α1-KO, but not α2-KO, enhanced ACh-induced artery dilation 
In view of the enhancing effects of CC on the ACh mediated dilation we studied the 
vasomotor responses to ACh in AMPK knockout mice. ACh is known to induce 
dilation in microvessels mainly via endothelium dependent hyperpolarization (EDH). 
Moreover, it has been shown that MEJs play a role in it. To test EDH dependent 
dilation, we pre-treated these arteries with L-NAME and INDO to inhibit NO and 
prostaglandin mediated effects. Dilation to ACh was significantly enhanced in AMPK 
α1-KO vessels compared to their respective WT controls and went along with 
respective calcium decreases (Figure 19). An enhanced dilation and calcium 
decrease to ACh was observed only in vessels from AMPK α1-KO mice but not in 
AMPK α2-KO vessels (Figure 20). 
 
 
58 
 
 
 
 
Figure 19. Left shift of the Ach dose response curve in AMPKα1-KO mice compared to 
their respective WT controls. 
Dilator effects of ACh in L-NAME and INDO treated muscle arteries from AMPK α1 WT and 
KO mice. (A, B): Representative diameter and  Calcium recordings of a single vessel each 
from both groups. (C and D): Dose effect curves of ACh showing a significant left shift of the 
dilation curve and an enhanced  calcium decrease in AMPK α1 KO arteries (Two way 
ANOVA, *p<0.05, ***p<0.001; AMPK α1 KO n = 6/3, AMPK α1 KO n = 7/4).  
59 
 
 
Figure 20. Ach dose response curve was not changed in AMPKα2-KO mice, compared 
to their respective controls (WT). 
Dilator effects of ACh in L-NAME and INDO treated muscle arteries from AMPK α2 WT and 
KO mice. (A, B): Representative diameter and  calcium recordings of a single vessel each 
from both groups. (C, D): Dose effect relations show no differences with regard to diameter 
and calcium (Two way ANOVA, n.s p>0.05.  AMPK α2 KO n = 9/5, AMPK α2 WT n = 4/3).  
3.6. More MEJs and IEL holes in AMPK α1-KO, but not in AMPK α2-KO mice. 
We also checked whether the knockout of AMPK α1 affects the number of IEL holes. 
Indeed, we found that the IEL hole number increased by 27.2 % (n=12 or 10) 
resulting in an respective increase of the hole (fenestrated) area (increase by 28.5.6 
% as compared to WT (Figure 21). Although the number of holes was higher the 
fraction of holes “containing”  MEJ also increased in AMPK α1-KO when compared 
with vessels of WT littermates in first branch mesenteric vessels (41.4 % ± 4.43 % 
AMPK α1-WT vs. 55.7 % ± 1.6 % AMPK α1-KO (t-test, ***p<0.001, n=8 or 4), as well 
as in muscle saphenous arteries (15.2 % ± 1.8 % AMPK α1-WT vs. 38.3 % ± 3 % 
AMPK α1-KO, (t-test, *p<0.05, n = 9 or 7)) (Figure 22). In AMPK α1-KO CC did not  
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any more increase the fraction of holes containing MEJ (55.7 % ± 1.6 % non-treated 
with CC vs 52.7 % ± 2.1% treated with CC (p>0.05, n=4)), whereas  it still did so in 
WT littermates from 41.4 % ± 4.4 % to  52.8 % ± 1.6 % (p<0.01, n=8) (Figure 23), 
whereas the fraction of holes filled with WLS did not differ between AMPK α2 WT and 
KO mouse arteries (Figure 24).  
  
Figure 21. The total hole area per unit IEL was higher in vessels of AMPKα1-KO mice. 
Mesenteric arteries from AMPK α1 WT and KO mice were analyzed with regard to IEL holes. 
(A): Representative images of IEL and its holes from AMPK α1 WT and KO mice. (B): The 
number of holes in IEL was significantly higher in AMPKα1 KO arteries as compared to WT 
(t-test, ***p<0.001, n = 12 or 10). (C): Likewise, the total hole area in IEL was significantly 
larger in AMPKα1 KO (t-test, *** p<0.001, n = 12 or 10).  Scale bar is 20 µm. 
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Figure 22. The fraction of hole filled with WLS was higher both in mesenteric and 
muscle arteries from AMPK α1-KO mice. 
(A): In mesenteric arteries a significantly higher fraction of holes filled with WLS was 
observed in AMPK α1 KO than WT littermates (t-test, ***p<0.001, n=8 or 4). (B): Similar 
results were obtained in skeletal muscle arteries (t-test, *p<0.05, n = 9 or 7).  
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Figure 23. Compound C increased the fraction of hole filled with WLS in mesenteric 
arteries from WT mice, but not in AMPK α 1 KO mice. 
The fraction of holes filled with WLS was significantly increased from 41.4 % ± 4.4 % to 52.8 
% ± 1.6 % when the arteries were treated with CC in WT but not in AMPK α1 KO arteries 
(55.7 % ± 1.6 % non-treated with CC % VS 52.7 % ± 2.1% treated with CC, n.s. p >0.05, 
n=4) (One Way ANOVA, **p<0.01, *** p<0.001, n = 8 or 4). 
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Figure 24. No difference with regard to the fraction of holes filled with WLS in 
mesenteric arteries between AMPKα2-KO and WT mice. 
Mesenteric arteries from AMPK α2 WT and KO mice showed no difference regarding the 
fraction of holes filled with WLS. There was no difference between WT and AMPK α2 KO 
arteries (t-test, n.s p>0.05, n=7 or 9 from three mice).  
 
3.7. PAI-1 expression was higher in AMPK α1-KO than WT artery, but not in 
AMPK α2-KO. 
To search the mechanism by which AMPK could regulate MEJ dynamics, we studied 
the expression of PAI-1 which has been shown a stimulator of MEJ (Heberlein et al. 
2010). For PAI-1 western blot, the whole mesenteric artery was isolated and equally 
divided into two parts. The vessels were then isolated and pooled for harvesting the 
proteins. The total AMPK (α1 and α2) in AMPK α1 KO was significantly reduced by 
41.2% as compared to AMPK α1 WT mouse MA (Figures 25 B and C). PAI-1 in 
AMPK α1 KO mice MA was significantly increased compared to WT littermates (t-test, 
p<0.05, n=6) (Figures 25 B and D). In contrast, both total AMPK and PAI-1 
expression in AMPK α2 KO mice MA were not different from their WT mice MA 
(Figure 26). 
64 
 
 
Figure 25. AMPK α1 KO arteries expressed more PAI-1 protein. 
(A, B): PCR and Western blot of single arteries demonstrating knockout of AMPK α1 subunit. 
(C): Reduction of the AMPK protein in KO mice (t-test, **p<0.01, n=4). Note that the antibody 
stains α1 and α2 subunits. (D):  Western blots revealed a significantly higher expression of 
PAI-1 in vessels of AMPK α1 KO mice (t-test, *p < 0.05, n=6).     
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Figure 26. No change of PAI-1 expression in AMPK α2 KO artery compared to WT. 
(A, B): PCR and Western blot of single arteries demonstrating knockout of AMPK α2 subunit. 
(C): No significant reduction of the total AMPK protein in KO mice (t-test, n.s p>0.05, n=3). 
Note that the antibody stains α1 and α2 subunits. (D): Western blots revealed no significant 
difference of expression of PAI-1 in vessels of AMPK α2 KO mice (t-test, n.s p > 0.05, n=3).  
3.8. Active-PAI-1 increased MEJs in intact artery. 
MAs from C57BL6/N mice were isolated, cannulated, pressurized, and incubated with 
active PAI-1 (1 µg / ml) or DMSO as control at 37 °C for 6 hours. After this, the 
arteries were co-stained with calcein-AM red-orange from the luminal side and Alexa 
633 from the abluminal side for the detection of MEJ and the IEL, respectively. PAI-1 
treatment significantly increased the fraction of holes covered by MEJ by 26.3% ± 
19.7% compared to the time control (n=4) (Figure 27).  
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Figure 27. Active PAI-1 increased the fraction of holes filled with WLS. 
Incubation with PAI-1 (or DMSO as control) for 6 hours significantly increased the fraction of 
holes filled with WLS. Values are normalized to the DMSO control (Mann-Whitney Rank Sum 
Test, * p<0.05, n=4). 
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3.9. AMPK activation reduced PAI-1 expression in intact artery. 
Single intact mesenteric arteries were isolated from C57BL6/N mice and treated with 
0.03% DMSO, A76 (10 µM) or A76 (10 µM) plus CC (10 µM) for 1 hour respectively, 
and then prepared for Western blot. The PAI-1 expression in arteries treated with 
A76 was significantly lowered by 39.9% of control arteries (n=6) (Figures 28 A and 
D). When A76 was combined with the AMPK inhibitor CC, the decrease of PAI-1 was 
blunted (One Way ANOVA, p<0.05, n=5 or 6) (Figures 28 A and D). The activation 
of AMPK by A76 as well as the inhibition by CC was assessed by the T172 
phosphorylation level of the alpha subunit and by the phosphorylation of classic 
AMPK substrate protein ACC. Both, AMPK T172 and ACC phosphorylation levels 
were significantly increased in arteries after incubation with the AMPK activator A76 
compared to DMSO control arteries (Figures 28 A, B and C). In A76 and CC treated 
arteries, the increase of p-ACC was virtually blunted compared to A76 treated 
arteries (One Way ANOVA, p<0.05, n=3). Surprisingly the AMPK T172 
phosphorylation level was even higher compared to other groups (Figures 28 A, B 
and C).  
In contrast, CC did not exert any effect on PAI-1 expression and ACC 
phosphorylation in unstimulated arteries after incubation for 1 hour. However p-
AMPK T172 was again significantly increased after incubation with CC compared to 
DMSO control (Mann-Whitney Rank Sum Test, p<0.05, n=3) (Figure 29). 
68 
 
 
Figure 28. Activated AMPK reduced the PAI-1 expression in intact artery. 
 (A): Representative western blot demonstrating AMPK activation by A76 and its inhibition by  
CC. (B): A76 significantly increased the phosphorylation of the AMPK target ACC which was 
inhibited by CC (One Way ANOVA,*p<0.05, n.s p>0.05, n=3). (C): Phosphorylation of AMPK 
T172 in intact arteries. The phosphorylation was significantly increased by A76 but was even 
higher after combined treatment with CC (One Way ANOVA, *p<0.05, **p<0.01, n=6 or 5). 
(D): PAI-1 expression in intact arteries was significantly lowered after AMPK stimulation with 
A76 (One Way ANOVA, *p<0.05, n.s p>0.05, n=5 or 6). Values are normalized to DMSO 
control. 
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Figure 29. CC alone did not affect PAI-1 expression in unstimulated arteries. 
 (A): Representative Western blot showing no effect of CC on PAI or ACC phosphorylation 
(B): No effect of CC on ACC phosphorylation (Mann-Whitney Rank Sum Test, n.s p>0.05, 
n=3). (C): p-AMPK T172 was significantly increased in arteries after incubation with CC 
similar as in A76 treated vessels (Mann-Whitney Rank Sum Test, *p<0.05, n=3). (D): PAI-1 
expression was not changed by CC treatment alone. (Mann-Whitney Rank Sum Test, n.s 
p>0.05, n=3). Values are normalized to DMSO control. 
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3.10. AMPK activation reduced the PAI-1 expression in PCASMC. 
Cultured PCASMC were used to study whether the AMPK effects observed in intact 
vessels occurred at the level of vascular smooth muscle. The cells (3-6 passage, 
confluent 70 %-80 %) were treated with 0.03 % DMSO, A76 (100 µM) and A76 (100 
µM) plus CC (15 µM) for 2 hours respectively, then detected the PAI-1 expression, p-
ACC and p-AMPK by Western blot. PAI-1 expression was significantly lowered 
compared to control after AMPK activation with A76. Again, pretreatment with CC, 
virtually blunted the decrease of PAI-1 (One Way ANOVA, Mann-Whitney Rank Sum 
Test, n=4, p<0.05) (Figures 30A and D). Like in intact vessels, AMPK T172 and 
ACC phosphorylation were significantly increased after A76 (Figures 30A, B and C). 
While co-incubation with CC again blunted the increase of p-ACC, the AMPK T172 
phosphorylation level was higher compared to other groups as observed in intact 
arteries (Figures 30A, B and C). 
 
 
 
 
71 
 
 
Figure 30. Activated AMPK reduced the PAI-1 expression in PCASMC. 
(A): Representative Western blot demonstrating phosphorylation of the AMPK, its substrate 
ACC, and expression of PAI-1 under A76. (B): ACC phosphorylation after AMPK stimulation 
and partial inhibition by CC (Mann-Whitney Rank Sum Test, *p<0.05, n=4) (C): AMPK T172 
phosphorylation was increased after A76 but further  increased after CC, similar as observed 
in intact arteries (Mann-Whitney Rank Sum Test, *p<0.05, n=4). (D): PAI-1 expression upon 
activation of AMPK was significantly lowered The AMPK inhibitor CC reversed this effect 
(One Way ANOVA and Mann-Whitney Rank Sum Test, *p<0.05, n=4). Values are 
normalized to DMSO control. 
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3.11. PAI-1 expression was increased after AMPK silencing with SiRNA in 
porcine and human VSM. 
Additionally, in order to detect the influence of AMPK on PAI-1 expression in smooth 
muscle cells, cultured PCASMCs and HUVSMCs were studied. Cultures were either 
transfected with Ctrl siRNA or siRNA designed to silence the expression of both    
AMPK α-subunits (α1 and α2). After three days, AMPK-siRNA significantly inhibited 
AMPK protein expression in both of the two different type VSMCs. In PCASMCs, the 
level of AMPK protein was down regulated by 64.5 % compared to control by siRNA 
treatment (t-test, p<0,001, n = 7) (Figures 31A and B). At the same time, PAI-1 
expression in siRNA AMPK cells was significantly enhanced by 2.9 ± 1.5 fold 
compared to siRNA ctrl cells (t-test, ***p<0.001, n=10) (Figures 31A and C). Similar 
results were obtained in HVUSMCs: the level of AMPK protein after siRNA treatment 
decreased by 69.7 % compared to control (t-test, p<0,01, n = 4) (Figures 32 A and 
B). Whereas the PAI-1 expression was significantly increased by 2.6 ± 0.6 fold (t-test, 
***p<0.001, n=4) (Figures 32A and C). 
 
Figure 31. AMPK silencing increased the PAI-1 protein expression in PCASMC. 
(A). Representative Western blot showing successful reduction of total AMPK (T-AMPK) 
expression and a concomitant increase in PAI-1 expression. (B): Total AMPK expression in 
siRNA AMPK cells was significantly lower than in siRNA ctrl cells (t-test ***p<0,001, n=7). 
(C): PAI-1 expression in siRNA AMPK cells was significantly higher than in siRNA ctrl cells (t-
test, ***p<0.001, n=10). Values are normalized to DMSO control. 
PAI-1 
T-AMPK 
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Figure 32. AMPK silencing increased the PAI-1 protein expression in HUVSMC. 
(A). Representative Western blot demonstrating successful reduction of total AMPK 
expression (T-AMPK). (B): Total AMPK expression in siRNA AMPK cells was significantly 
lower than in siRNA ctrl cells (t-test **p<0.01, n=4). (C): PAI-1 expression in siRNA AMPK 
cells was significantly higher than in siRNA ctrl cells (t-test, ***p<0.001, n=4). 
3.12. PAI-1 expression was not significantly changed after AMPK silencing in 
HUVEC. 
In order to detect the influence of AMPK on PAI-1 expression in endothelial cells, 
HUVEC were studied. The cells were transfected with AMPK siRNA (including α1 
and α2 subunits) or Ctrl siRNA for two days, then harvested and lysed. siRNA AMPK 
treatment inhibited AMPK protein expression by 42 % of control (t-test, p<0,001, n=7) 
(Figures 33 A and B). However, PAI-1 expression in siRNA AMPK cells was not 
significantly altered (t-test, p>0.05, n=7) (Figure 33 A and C). 
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Figure 33. AMPK silencing did not change the PAI-1 protein expression in HUVEC. 
(A): Representative Western blot demonstrating partial reduction of total AMPK (T-AMPK) 
protein after siRNA treatment. (B): Total AMPK expression in siRNA AMPK cells was 
significantly lower than in siRNA ctrl cells (t-test, ***p<0,001, n=7). (C): In contrast to smooth 
muscle cells, PAI-1 expression in siRNA AMPK EC was not significantly changed compared 
to siRNA ctrl cells (t-test, n.s p>0.05, n=7).  
3.13. SHP expression was inhibited in vessels of both AMPK α1 and AMPK α2-
KO mice. 
SHP has been reported to play a pivotal role on the transcriptional repression of 
many genes (Seol et al. 1996) including PAI-1. Total AMPK in AMPK α1 KO mouse 
MA was significantly reduced by 41.2% as compared to AMPK α1 WT mice MA 
(samples were the same which were used for detection of PAI-1) (Figures 25B and 
C), SHP in AMPK α1 KO mouse MA was significantly decreased as compared to 
AMPK α1 WT mouse MA (p<0.001) (Figure 34). However, virtually the same 
changes were observed in AMPK α2 KO mouse MA, SHP was significantly 
decreased in vessels of AMPK α2 KO mouse MA as well (t-test, **p<0,01, n=3) 
(Figure 35). 
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Figure 34. Lower SHP expression in AMPK α1 KO mice. 
(A): Representative Western blot. (B): SHP expression was significantly lower in AMPK α1 
KO than in WT mouse arteries (t-test, *p < 0,05, n = 7/5). Values are normalized to AMPK α1 
WT mouse artery. 
 
 
Figure 35. Lower SHP expression in AMPK α2 KO mice.  
(A): Representative Western blot. (B): SHP expression in AMPK α2 mouse arteries was 
significantly lower in AMPK α2 KO than in WT mouse arteries. (t-test, **p<0,01, n=3). Values 
are normalized to AMPK α2 WT mouse artery. 
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4. Discussion 
4.1. A short recapitulation of the most important findings. 
In this thesis, results are presented which support a novel role of AMPK, in particular 
its alpha1 subunit, in controlling the formation of cell protrusions / MEJs. AMPK 
exerts its effects by modulating PAI-1, most likely via the SHP pathway. These 
findings were made in intact microvessels in which MEJs are known to play an 
important role in the control of vascular tone via EDH. Indeed, the magnitude of EDH 
dependent dilation by acetylcholine correlates well with changes in the expression of 
MEJ in these vessels. For the first time we can observe the dynamics of the 
formation of MEJ. Complementary studies in cultured smooth muscle cells suggest 
that the effect of AMPK occurs predominantly at the level of vascular smooth muscle. 
4.2. Research models for MEJ.  
Our studies were performed in intact small blood vessels which allow studying cell- 
cell contacts of MEJ in a physiological environment especially with respect to their 
dynamics which have not been in focus so far. Many, more artificial, models to study 
EC-VSMC communications via MEJ have been reported. EC-VSMC co-culture 
models allow investigation of intercellular communication, as well as the influence of 
co-culture on VSMC’s protein expression and morphology (Wallace et al. 2007) Since 
cells can be better manipulated and connexin expression can be better controlled, 
this model allows to study regulation and permeability of MEJ, though these cells 
may lack some components present in intact vessels such as IEL proteins. Our 
laboratory has successfully used this model to study the regulatory effect of NO on 
calcium propagation via MEJ (Pogoda et al. 2014). A model which allows to study 
myoendothelial interactions and to harvest tissue components enriched in MEJ is a 
model where cultured EC and VSMC are cultured on opposite sides of transwell 
filters which to some extent mimics the vessel biological structure (D’Amore 1992; 
Fillinger et al. 1993). One of the major features of this model is that there is a 
membrane between EC and VSMC which separates the cells as the IEL does and 
spatially structures EC and VSMC interaction in a similar way as the IEL does. Due to 
these characteristics, this model is widely applied to investigate the MEJ functions in 
77 
 
vascular wall biology (Isakson & Duling 2005; Heberlein et al. 2010; Gairhe et al. 
2011; Zhang et al. 2016; Jing Xu et al. 2017). There are also some other models, 
such as EC-VSMC co-culture separated with collagen gels (van Buul-Wortelboer et 
al. 1986), and spheroid-bound EC-VSMC co-culture (Korff et al. 2001). Recently, the 
three-dimensional sandwich co-culture model has also been created. In this model, 
EC and VSMC are separated by the membrane which is produced by VSMC 
autonomously, and they can contact each other closely by puncturing the membrane 
(Ganesan & Finsterwalder 2016). A common shortcoming of these models is that 
they rely on the properties of cultured cells. However culture conditions may 
decisively alter the characteristics of cells and their mutual interaction (Abdeen et al. 
2016). Moreover, these models are not suitable to assess simultaneously for 
potential effects of MEJ manipulation on vascular tone which is only possible in intact 
vessels. This is an advantage of our model. Moreover, this model allows to study the 
dynamic behavior of cell-cell contacts and MEJ without potential alterations by culture 
conditions. The intact, cannulated vessel under physiological pressure, also known 
as the pressure myograph system, has been widely applied in vessel function 
research (Holger. Schneider et al. 2015; Schubert et al. 2017). Using this model, we 
can now confirm that an actin bridge, which has been described as a typical marker 
of MEJ in cell culture systems (Isakson, A. Best, et al. 2008; Heberlein et al. 2013), 
can also be observed in MEJ in situ. This actin bridge could be detected when using 
LifeAct mice. LifeAct is a peptide analogous to the first 17 aa of the actin binding 
protein 140, and can be used as a F-actin marker in mammalian cells. LifeAct can 
bind to F-Actin and can be detected by fluorescence microscopy when it is tagged 
with GFP (Riedl 2010). The transgenic LifeAct mouse is widely used to study the F-
actin dynamics in intact cells  (Richter et al. 2010). Our findings in small arteries of 
LifeAct mice could be confirmed using the F-actin staining compound phalloidin 
(Riedl 2010), which however could only be obtained under static conditions, since the 
cells need to be permeabilized for phalloidin to reach the cellular actin (Faulstich et 
al. 1980). Much to our surprise we found that incubation of endothelial and smooth 
muscle cells in situ with the calcium indicator calcein reproduced exactly the same 
imaging of the structures that were obtained with LifeAct and phalloidin. It is not clear 
at present, that calcein binds to actin and it should be emphasized that calcein 
staining did not reproduce the pattern of LifeAct actin staining throughout the whole 
cell but rather in MEJ. It is therefore more likely that the dynamics of F-Actin 
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formation in MEJ may require local elevation of calcium (eliciting local calcein 
fluorescence) that comes from the adjacent endoplasmic reticulum which is a cellular 
calcium store. However, more studies are necessary to prove this explanation. 
Nevertheless, calcein staining allowed us to study the formation of MEJ and to 
dispense LifeAct which gave us better possibilities to stain other structures 
simultaneously. 
4.3. Cell protrusions and / or MEJ? 
Using microscopic techniques we identified primarily wheel like structures (WLS)with 
spokes and a hub consisting of F-actin. These structures had diameters between 5 
µm and 9 µm which may comprise the range of diameters of fully developed and 
growing and of vanishing cell protrusions as well. We know from electron microscopic 
studies that gap junctions are usually clusters of intercellular channels which cover a 
whole area of connexons in the cell membrane (Sosinsky & Nicholson 2005), 
obviously still much smaller than the observed WLS. As a consequence we did not 
directly observe gap junctions. We propose, however, that all these WLS contained 
gap junctions for the following reasons. Actin-rich structures along cell membranes 
have been found to be the scaffold for functional microdomains such as MEJ, 
podosomes and focal adhesions (Isakson, A. K. Best, et al. 2008; Murphy & 
Courtneidge 2011; Yamin & Morgan 2012). We could distinguish these cell 
protrusions from podosomes produced by in EC and VSMC since they had no direct 
contact to each other and showed a different staining pattern e.g with cortactin and 
MMP-14. The podosomes were even more dynamic actin structures with a clear 
circular assembly. They also showed a different localization than the actin rich WLS 
and could not be assigned to holes in the IEL. In contrast the cone-like structures 
characterized as WLS were always located in IEL holes and stained positive for 
Cx37, Cx43, and PAI-1 proteins which are enriched in MEJ (Isakson, A. K. Best, et 
al. 2008; Heberlein et al. 2012). MEJs were located in holes of the IEL the only sites 
which allow direct gap junctional contact of VSM and EC in these small vessels 
(Straub et al. 2014).  
Moreover, the amount of WLS as quantified by fluorescent microscopy in our vessels  
were expressed to the same amount as observed with independent methods such 
electron microscopy in vessels of similar size (Sandow et al. 2009). Thus, we 
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conclude that the WLS allowed us to study indirectly the myoendothelial gap 
junctions present in these vessels.  
4.4. Dynamics of MEJs vs.  connexins / Gap junctions. 
Gap junction function can be regulated acutely via phosphorylation of the key 
residues on connexin subunits (Segal & Bagher 2010). Our group has found that NO 
can modulate calcium signal propagation through MEGJ by protecting Cx37 from 
dephosphorylation at Y332 via inhibition of the phosphatase SHP-2 (Pogoda et al. 
2014; Pogoda et al. 2017). The gap junction protein complexes in the cell membrane 
undergo hourly high turnover with half life times around two hours (Segal & Bagher 
2010). For example, connexin 26, connexin 30 and connexin 43 can be down-
regulated within 6 hours of wounding at the wound edge (Davis et al. 2013). But only 
few studies focus on the kinetics of MEJ formation and regression (Heberlein et al. 
2010). Until now, there is no information about the detection of MEJ dynamics in 
intact arteries. To the best of our knowledge, in this project, we can present for the 
first time results on the dynamics of MEJs, observed here as WLS structures. We 
were, however, not able to study whether all MEJ also contained MEGJ. Dynamic 
changes could be observed in the presence of the gap junction inhibitor compound 
C, whereas the vessels of AMPK a1 KO mouse reflected a new steady state. The 
effect of CC was specific, since in AMPKa1 KO mice, it did not increase MEJ any 
further. Interestingly acute AMPK stimulation did not acutely reduce the number of 
MEJ, which could suggest a full inhibitory effect already of basal AMPK activity in the 
cells.   
4.5. MEJ as interactomes 
MEJ represent important EC-VSMC signal communication domains in the resistance 
artery wall (Straub et al. 2014) which are enriched in channels, enzymes and 
regulatory molecules. For example, it has been demonstrated that the endoplasmic 
reticulum (ER), caveolae and ribosome organelles are enriched in MEJ in vitro and in 
vivo (Straub et al. 2011; Isakson et al. 2007; Heberlein et al. 2013). ER enrichment at 
MEJ may be required to serve as local calcium pool which is important for the local 
activation of cell signaling cascades. There is also evidence the ER is enabling local 
protein translation in the area (Straub et al. 2014). In the current study, using ER-
Tracker™ ER-Bodipy staining in the living, intact artery we could show the presence 
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of ER in the MEJ. ER-Tracker™ ER-Bodipy dye is a live-cell stain and highly 
selective for ER (Zünkler et al. 2004). It has also been confirmed that scaffolding 
proteins such as actin and microtubules, are extensively localized in MEJ (Isakson, 
A. Best, et al. 2008). This is considered important for protein trafficking towards these 
areas. The enrichment of F-actin in MEJ could be detected in living LifeAct as well as 
after fixation and phalloidin staining.  
MEJ play also a critical role in the tone regulation of resistance arteries (Straub et al. 
2014). Nitric oxide (NO) is an important dilator, and endothelial NO synthase also 
localizes in MEJ (Straub et al. 2011; Straub et al. 2012). In resistance arteries, 
endothelial dependent hyperpolarization (EDH) is considered functional more 
important than NO signaling. Most of EDH related channels and proteins, (such as 
transient receptor potential 4 (TRPV4), IP3-R, Na+/K+ -ATPase, KIR channel, SKca 
channels and BKca-channel) (Ledoux et al. 2008; Tian & Xie 2008; Sonkusare et al. 
2012; Absi et al. 2007), as well as epoxyeicosatrienoic acid and caveolin-1 are 
enriched in MEJ (Isshiki & Anderson 2003). Connexins were also  been shown to be 
enriched in MEJ (Langlois et al. 2008) and they may not only function to firm gap 
junctions but also serve as scaffolds for protein complexes (Pogoda et al. 2017).  
4.6. AMPK, a universal cell regulator. 
AMPK is a heterotrimeric enzyme including a catalytic α subunit and two regulatory 
subunits β and γ, with a different combination and unequal distribution in diverse 
tissues (Hardie 2007). It has been characterized as a critical sensor of cellular energy 
status in all eukaryotic cells and can be activated by the increase in AMP:ATP and 
ADP:ATP ratios (Lin & Hardie 2017). In general, AMPK inhibits anabolic metabolism 
to restore energy, and promotes catabolic metabolism to generate ATP (Garcia & 
Shaw 2017). These catabolic processes include glucose uptake, glycolysis, fatty acid 
oxidation and mitochondrial biogenesis (Hardie 2008). All of these processes require 
the supply of cells with substrates and oxygen which is delivered by blood flow. 
Enhancement of catabolic metabolism therefore implies that the microcirculation 
allows a higher blood flow which can be achieved when resistance arteries dilate. 
Indeed, we have found before that AMPK activation can dilate resistance artery via 
calcium-dependent and -independent pathways (Holger. Schneider et al. 2015; 
Schubert et al. 2017).  
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4.7. AMPK expression in blood vessels. 
AMPK is expressed both in endothelium and smooth muscle (Stahmann et al. 2010; 
Pyla et al. 2015), and exerts an important function for the regulation of vascular tone 
(I. P. Salt & Hardie 2017). In our former studies we have described that all of the 
isoforms of  AMPK α (α1 and α2) and β (β1 and β2) subunits are expressed in 
hamster microvascular system (Holger. Schneider et al. 2015). Like others, we find 
that AMPK α1 is the major isoform and accounts for the majority of total AMPK in 
vascular system (Francoise Goirand et al. 2007; Stahmann et al. 2010). Our results 
obtained in this study from intact small mouse arteries also show the knockout of 
AMPK α1 but not of AMPK α2 went along with a drastic reduction of the total AMPK α 
expression in western blots, further supporting the view that AMPK α1 was the 
predominantly expressed catalytic isoform. The subcellular distribution of AMPK in 
various cell types has been shown to be very different, which  seems to be 
dependent on the subunit composition with a more dispersed subcellular distribution 
of AMPK α2 and γ2, and predominantly cytoskeletal location of α1 and γ1 subunits 
(Pinter et al. 2013; Pinter et al. 2012). In heart, the AMPK γ2 subunit has been found 
to co-localize with the T-tubule system and SERCA2 (Pinter et al. 2013). 
Furthermore, we have found previously that AMPK is essential for SERCA function 
via regulating the phosphorylation status of PLN on Thr17 in VSMC of small arteries 
(Holger. Schneider et al. 2015). Moreover, in a study conducted in pancreatic cells, 
AMPK was capable to change ER (inhibition caused ER expansion and ER stress) 
and mitochondrial morphology via phosphorylation and thus regulating Dynamin-
related protein 1 (DRP-1) (Wikstrom et al. 2013). AMPK activation is also involved in 
regulating the F-actin dynamics (Schubert et al. 2017) in smooth muscle cells. F-actin 
cytoskeletal components are enriched in MEJs as shown here by us and before by 
others (Heberlein et al. 2009).  
4.8. Verification of the AMPK activation state 
It is important for the interpretation of our findings to confirm that AMPK stimulators 
indeed activated AMPK. On the other hand it is important to verify that siRNA 
treatment as well as treatment with the unspecific pharmacologic inhibitor of AMPK, 
compound CC really affected expression or in the latter case – the activity of the 
enzyme. According to the literature as an indicator for activation of AMPK, two 
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protein phosphorylation are accepted. One is the phosphorylation of Thr-172 of the 
AMPK alpha units (S. a Hawley et al. 1996). The other one is the phosphorylation 
state of its direct cellular substrate acetyl-CoA carboxylase (ACC) (Salt & Hardie 
2010; C. Zhang et al. 2017). Higher level of ACC phosphorylation are indicating 
stronger AMPK activation. Here we could indeed show that treatment with A76, an 
activator of AMPK, significantly enhanced AMPK phosphorylation at Thr-172 and 
ACC phosphorylation in intact vessels, which is in accordance with former studies in 
animal and culture cells (Göransson et al. 2007).  Conversely, treatment with CC or 
treatment with siRNA reduced ACC phosphorylation as expected, thus confirming 
efficacy of the treatment.  
However, CC unexpectedly also increased AMPK α phosphorylation at Thr-172. This 
is at variance with several studies (Chakrabarti et al. 2015; Zhou et al. 2017), but at 
least one study in yeast cells showed that binding of a adenylate ligand at the 
interface between AMPK kinase domain and the heterotrimeric core can significantly 
reduce AMPK’s catalytic activity without affecting phosphorylation level of Thr 172 
(Chandrashekarappa et al. 2013). Since it is not known how CC exactly acts as the 
inhibitor of AMPK, it is possible that Thr172 phosphorylation is not a reliable indicator 
of AMPK activity in the presence of CC. 
4.9. AMPK α1 modulation of MEJ dynamics 
In our experiments we observed that arteries of AMPK α1 KO mice expressed 
significantly more WLS. This was not the case in AMPK α2 KO which suggests that 
the effect was dependent on AMPK α1. Though proper littermates were used as 
control, these experiments alone cannot exclude that the effect was only an indirect 
one based on unspecific side effects of chronic AMPK rundown. However we could 
show that treatment with CC and acute siRNA treatment had the same effects within 
a few hours, i.e an acute increase of the number of WLS in intact vessels which to 
our knowledge is the first time that short term, dynamic alterations of WLS formation 
could be observed. We therefore conclude that AMPK via the α1 subunit reduces the 
formation of WLS and hence of MEJ. Such an effect of AMPK has not yet been 
described before.  
Using co-culture models Heberlein et al. have described that less MEJs went along 
with less formation of actin bridges (Heberlein et al. 2010). Therefore it is possible 
83 
 
that part of the AMPK effects are due to inhibitory AMPK effects on F-actin formation. 
We have shown before, that AMPK can degrade F-actin via activation of the actin 
severing protein cofilin (Schubert et al. 2017).  
4.10. AMPK regulates MEJ dynamics via PAI-1. 
Our findings suggest that AMPK is exerting its inhibitory effects on MEJ at least in 
part via downregulation regulating PAI-1 expression. Indeed PAI-1 consistently 
showed changes which were inverse to changes of AMPK activity or expression 
under such different conditions as genetic AMPK knockout, siRNA treatment and 
pharmacological inhibition in vascular smooth muscle.  
This is in accordance with a report demonstrating that PAI-1 gene can be down-
regulated via AMPK pathway (Chanda et al. 2009). A signaling cascade  comprising 
adiponectin-AMPK-PAI-1 was also shown to play a significant role in the gender 
specific difference regarding susceptibility to develop nonalcoholic fatty liver disease 
(NAFLD) (Spruss et al. 2012). 
Local translocation and knock-out models of PAI-1 have suggested that this 
compound, also elevated under obese conditions, is essential for MEJ formation with 
more MEJ formed with higher PAI-1 amounts (Heberlein et al. 2010; Heberlein et al. 
2013). Other authors have also described a similar effect of PAI-1 on MEJ in murine 
corporal tissue vessel system (Kavoussi et al. 2015). 
Interestingly, Heberlein et al also have shown that the amount of PAI-1 expressed 
depends on microtubule binding ability and local translation of PAI-1 mRNA at the 
rough ER near MEJ (Heberlein et al. 2012). AMPK can also modulate microtubule 
stability via phosphorylation of CLIP-170 (Nakano et al. 2010) and ER function by 
SERCA (Holger. Schneider et al. 2015).  
PAI-1 does not only influence coagulation and fibrinolysis, but  has been shown to 
have other functions (Rijken & Lijnen 2009). In the context of MEJ, it may play a 
compensatory role to maintain MEJ dependent endothelial dependent 
hyperpolarization and dilation in obesity, as elevated amounts of MEJs were found in 
the coronary arteries of C57Bl/6 mice fed with a high-fat diet. This went along with an 
elevation of PAI-1 levels (Heberlein et al. 2010). In the same study, they also found a 
faster endothelial Ca2+-increase to phenylephrine in a vascular cell co-culture model 
84 
 
when recombinant PAI-1 was present. Since only smooth muscle cells respond to 
phenylephrine , the increase in endothelial calcium was considered to be due to MEJ 
calcium transfer (Heberlein et al. 2010).  
It is not yet clear however, how AMPK regulates PAI-1 expression. PAI-1 synthesis is 
regulated by many factors and on many levels (Agirbasli 2005). Its expression can be 
stimulated by inflammatory state (Emeis & Kooistra 1986; Sawdey et al. 1989) and 
hypoxia in human EC etc. (Gerber et al. 1993). High fat diet and TNF-α stimulation 
facilitate the increase of PAI-1 by stabilization of PAI-1 mRNA at MEJs location via 
mRNA binding protein-serine binding protein-1 (Heberlein et al. 2012). Recently, it 
was shown in HepG2 cells that AMPK can negatively regulate PAI-1 via increase of 
the silencer small heterodimer partner (SHP) (Chanda et al. 2009). Our current study 
shows that SHP was indeed down-regulated in AMPK α1 KO mice which would result 
in an increased PAI-1 expression as observed. However, such a downregulation was 
also observed in vessels of AMPK α2 KO mice which did not show alterations in 
MEJ. Thus, more research appears to be necessary to elucidate the concrete 
mechanism of AMPK modulating PAI-1 expression. 
4.11.  Endothelial vs. smooth muscle regulation 
Of note, western blots of small isolated vessels do not help to differentiate between 
whether changes of protein expression occur in the endothelium or in smooth 
muscle. There are techniques to remove the endothelium such as perfusion with air 
(Holger. Schneider et al. 2015) but complete removal cannot be confirmed when the 
vessel is supposed to be used for western blot. Thus, we performed further studies 
using cultured cells. These could not be isolated in sufficient amounts and purity from 
the small vessels so that endothelial cells from other origin and species had to be 
used, HUVEC and porcine or human coronary artery smooth muscle cells. 
Interestingly, all findings from isolated vessels could be confirmed in cultured smooth 
muscle cells using siRNA and Compound C. In contrast, in HUVEC, PAI-1 was not 
significantly changed with silencing of AMPK. The results may be species or tissue 
specific. Alternatively, the endothelial AMPK was not suppressed sufficiently so that 
the residual AMPK could still exert an effect on PAI-1 expression. This requires 
further research especially since the work of Heberlein et al appears to indicate that 
PAI-1 changes at the endothelial side are important for the effects on MEJ which they 
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observed (Heberlein et al. 2010). Of note, data from arteries of inducible endothelial 
AMPK α1 KO mice showed a loss of EDH function (Enkhjargal et al. 2014) whereas 
we found an increase  in a global knockout model, i.e. after (additional) KO of smooth 
muscle AMPK. 
4.12. ACh-induced dilatation in AMPK α1 KO mice: related to the higher 
amount of MEJ?  
In many studies including some from our own lab (Steffen-Sebastian Bolz et al. 1999; 
Hoepfl et al. 2002) it has been shown that acetylcholine (ACh) elicits an endothelium 
dependent dilatation. The endothelium dependency of ACh mediated dilation has 
been shown by us before in the mesenteric arteries, the same vessels type  which 
was studied here (Pogoda et al. 2017). When ACh binds with its receptor on EC, 
mainly M1 and M3, VSMC dilators (NO, PGI and EDHFs) are produced, and these 
dilators induce VSMC relaxation (Rubanyi 1991). NO and PGI are synthesized by 
nitric oxide synthase (NOS) and cyclooxygenase respectively from their respective 
precursors L-arginine and  arachidonic acid (Shu et al. 2015; Hara 2017) and diffuse 
from EC to VSMC to elicit dilation. Their formation can be inhibited by the NOS 
inhibitor L-NAME and the cyclooxygenase inhibitor INDO respectively. Endothelium 
dependent hyperpolarization (EDH) also leads to vasodilation of smooth muscle. 
There is some evidence that several EDHFs can be  produced by the endothelium to 
elicit vasodilation (Garland & Dora 2017). Potassium ions which are released from 
the endothelium after activation of SKca and IKca channels (Rasmussen et al. 2016) 
are thought to represent one EDHF since they can hyperpolarize underlying smooth 
muscle cells by activation Kir channels AND Na
+/K+ ATPase (Jackson 2017). 
Endothelial potassium channels are enriched in myoendothelial junctions (Ledoux et 
al. 2008; Tian & Xie 2008; Sonkusare et al. 2012; Absi et al. 2007). This is the 
potential basis for the findings first reported by Tudor Griffith, that “EDH” effects 
require the presence and intact function of  MEJ (Griffith et al. 2004). The calcium in 
VSMC will increase and induce VSMC contraction when ACh directly binds to the M1 
or M3 on VSMC (Rourke & Vanhoutte 1992) but this effect is weak and does not 
affect the net dilation observed with intact endothelium. 
In accordance with this, we found that in small arteries exhibiting higher amounts of 
WLS/MEJ there was an enhanced ACh induced endothelium dependent dilation. This 
86 
 
dilation was elicited in the continuous presence of L-NAME and Indo which excludes 
NO and PGI2 as mediators so that it was an EDH-induced dilation confirming that 
MEJ plays an important role for this type of dilation. It should be mentioned here, 
however, that our findings obtained with CC do not fully support this conclusion. 
While we could show that CC increases the amount of MEJ, we also observed a 
reduction of the calcium signal passing into smooth muscle cells from endothelium, 
suggesting a reduction of MEJ permeability. This may be due to an unspecific effect 
of CC on gap junction permeability which reduces the transfer in spite of a higher 
number of MEJ. Though we consider it unlikely, we can also not exclude at this point 
that AMPK KO could also have some changes of MEJ permeability which would 
make it difficult to assume a linear correlation between the number of MEJ and the 
resulting dilation.    
4.13. Potential physiological relevance of the mechanism. 
The  vast majority of studies have shown that AMPK activation is beneficial for artery 
relaxation and blood flow (E. a Bradley et al. 2010; Enkhjargal et al. 2014; Wang et 
al. 2012; Ford & Rush 2011), For example, AMPK inhibition and deletion has been 
reported to be neuroprotective and reduce infarct size (Li et al. 2007). 
In accordance with this we have also shown that AMPK is a potent vasodilator which 
exerts its dilator effects at the level of vascular smooth muscle by reducing  the 
cytosolic calcium level and the calcium sensitivity of the contractile apparatus 
(Holger. Schneider et al. 2015; Schubert et al. 2017). 
Under these conditions it is difficult to understand why AMPK should reduce 
expression of MEJ. A recent study from our lab, analyzing the effect of NO on Cx37 
dependent control of MEJ permeability appears to shed some light on this question 
(Pogoda et al. 2014; Pogoda et al. 2017). In this work it could be shown that an 
inhibition of MEJ permeability preserved endothelial calcium losses towards the 
underlying smooth muscle and increased endothelial sensitivity to vasoactive 
agonists. Therefore, too many MEJ could reduce endothelial vasomotor function 
implying that the number of MEJ needs to be tightly regulated.  It is also conceivable 
that we observe a compensatory mechanism: when AMPK dilation is reduced, e.g. in 
obesity being characterized by reduced levels of the endogenous AMPK stimulator 
adiponectin, an increased EDH could partly compensate for it.  
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In summary, our study provides first data on MEJ dynamics. In the model of isolated 
intact vessels, MEJ regulation can be studied while the cells remain in their natural 
environment. The data also provide evidence for a hitherto unknown role of AMPK in 
the regulation of MEJ expression. Further studies have to show whether this 
disturbances of this function and related changes of PAI-1 expression, e.g. in 
inflammation, have pathophysiologic relevance and whether specific treatment of 
AMPK activity will offer new therapeutic options. 
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